

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Hearing loss associated with rheumatoid arthritis: a nationwide retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018134
Article Type:	Cohort profile
Date Submitted by the Author:	15-Jun-2017
Complete List of Authors:	Huang, Chung-Ming Chen, Hsuan-Ju; China Medical University Hospital Huang, Po-Hao Tsay, Gregory J Lan, Joung-Liang Sung, Fung-Chang
Primary Subject Heading:	Rheumatology
Secondary Subject Heading:	Epidemiology, Ear, nose and throat/otolaryngology
Keywords:	Rheumatoid arthritis, hearing loss, insurance data,, retrospective cohort study

SCHOLARONE™
Manuscripts

1
2
3
4 **Hearing loss associated with rheumatoid arthritis: a nationwide**
5
6 **retrospective cohort study**
7
8

9 Chung-Ming Huang^{1,2}, Hsuan-Ju Chen^{3,4}, Po-Hao Huang¹, Gregory J Tsay¹,
10
11
12 Joung-Liang Lan¹, Fung-Chang Sung^{3,5}
13
14

15 **Running Title:** Hearing loss in rheumatoid arthritis
16

17
18 ¹Division of Immunology and Rheumatology, Department of Internal Medicine,
19
20 China Medical University Hospital, Taichung, Taiwan;
21
22

23 ²Graduate Institute of Integrated Medicine, College of Chinese Medicine, China
24
25 Medical University, Taichung, Taiwan
26
27

28
29 ³Management Office for Health Data, China Medical University Hospital, Taichung,
30
31 Taiwan
32
33

34 ⁴College of Medicine, China Medical University, Taichung, Taiwan
35
36

37 ⁵Department of Health Services Administration, China Medical University, Taichung,
38
39 Taiwan
40
41

42 Corresponding author:

43 Fung-Chang Sung, PhD, MPH

44 Department of Health Services Administration, China Medical University

45 91 Hsueh Shih Road

46 Taichung 404, Taiwan

47 Tel: 886-4-2205-4070

48 Fax: 886-4-2233-9216

49 E-mail: fcsung1008@yahoo.com
50
51
52

53
54 Word count: Abstract, 186; Text, 2232; Tables, 3; Figures, 2
55
56
57
58
59
60

ABSTRACT

Purposes:

Hearing loss (HL) has been reported as a manifestation of systemic vascular involvement in patients with an autoimmune disease. However, population studies on HL associated with rheumatoid arthritis (RA) are lacking. This study aimed to investigate the risk of developing HL in patients with RA using a nationwide cohort.

Participants:

We used the National Health Insurance Research Database (NHIRD) of Taiwan from 2000 to 2006 and identified 18,267 patients newly diagnosed as having RA and 73,068 subjects without RA who were frequency-matched by sex, age, and index year. We estimated incidence of HL in both cohorts and the RA cohort to non-RA cohort hazard ratios (HRs) adjusted for sex, age, and comorbidities.

Findings to date:

The incidence of HL was higher in the RA cohort than in the non-RA cohort (3.08 versus 1.62 per 1000 person-years), with an adjusted HR of 1.89 (95% confidence interval = 1.68-2.12) for the RA cohort relative to the non-RA cohort after controlling for age, sex, and comorbidities. Men were at a higher risk than women, and the risk

1
2
3
4 increased with age. Cardiovascular comorbidities were consistently associated with a
5
6 high HL risk in patients with RA compared with those without RA.
7
8
9

10 **Conclusions:**

11
12
13
14 This nationwide population-based retrospective cohort study demonstrates that
15
16 patients with RA are at an elevated risk of developing HL. Moreover, cardiovascular
17
18 comorbidities could increase HL risk.
19
20
21
22

23 **Keywords:** Rheumatoid arthritis, hearing loss, insurance data, retrospective cohort
24
25 study
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

review only

Strengths and limitations of this study

1. The strength of this study is the use of a nationwide population-based cohort to identify HL risk in an Asian population with RA. Our findings can be generalized to the general population.
2. The large sample size allowed the identification of risk factors associated with the development of HL in Taiwan with a minimal tendency for selection bias, and enhanced the statistical power and precision of risk appraisal.
3. In addition, the inclusion of the Catastrophic Illness Patient Database (CIPD) confirmed the diagnoses of all RA cases in the NHIRD database, which increased the reliability of our data.
4. several limitations to the interpretation of our findings should be considered. Information on several suspected risk factors for HL, such as smoking and chronic exposure to occupational and environmental noise, which could be associated with HL in the general population, were not available in the insurance database.
5. Moreover, information on laboratory test results or HL severity was not available in the insurance claims data, and data on RA severity scale, such as disease activity, functional impairment, and physical damage, was also unavailable.

Introduction

Rheumatoid arthritis (RA) is a disease predominantly characterized by chronic joint inflammation and is often accompanied by several peripheral inflammatory manifestations [1]. RA may lead to the destruction of the cartilage and bone due to chronic synovitis and may consequently impair joint function [2]. In addition, patients with RA may have extra-articular manifestations involving other organ systems [3], such as auditory system alteration, although with a different putative mechanism of damage [4–6]. With respect to the auditory system, previous studies have shown conflicting findings, both as to the types of hearing loss and as to the RA disease activity and severity associated with hearing levels [7-10].

A wide variation in the reported prevalence of different types of hearing loss in patients with RA exists. Sensorineural hearing loss (SNHL) is the most common hearing impairment in patients with RA, ranging from 25 to 72% [11], whereas conductive hearing loss and mixed hearing loss are less frequently reported [12-14]. SNHL could be induced by a direct immune response of either T or B cells against inner ear proteins [15]. Neurovascular inflammation and drugs used for RA treatment could also damage the cochlea [16]. Thus, hearing loss (HL) may be a manifestation of systemic vascular involvement in patients with RA and may have a significant effect on the health of patients with RA. However, the risk of developing HL in

1
2
3
4 patients with RA has not been well examined using population data.
5

6 Hence, the purpose of this study was to investigate the HL incidence in patients
7
8 with RA. Using representative insurance claims data obtained from the Taiwan
9
10 National Health Insurance (NHI), the risk of developing HL in patients with RA was
11
12 examined. The effects of comorbidities, such as coronary heart disease, hypertension,
13
14 stroke, diabetes, hyperlipidemia, hyperthyroidism, and chronic renal disease, on the
15
16 risk of developing HL were also evaluated.
17
18
19
20
21
22

23 **Materials and Methods**

24 **Data source**

25
26
27 The Taiwan NHI system is a single-payer compulsory programme with a
28
29 coverage of over 99% of 23.74 million people [17]. We conducted this study using
30
31 two data sets: the Registry for Catastrophic Illness Patient Database (CIPD) and the
32
33 Longitudinal Health Insurance Database (LHID2000) from the Taiwan National
34
35 Health Research Institutes. The registry for CIPD contains health claims data of
36
37 patients who had major diseases, such as cancer, chronic mental illness, end-stage
38
39 renal disease, and several autoimmune diseases requiring long-term care, and who
40
41 were eligible for exemption from making co-payment. The LHID2000 contains the
42
43 claims data of 1,000,000 people randomly sampled from all populations that
44
45 registered in 2000 for the insurance coverage. Reimbursement claims data for medical
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 services from 1996 to 2011 in both data sets were also used in this study. For privacy
5
6 protection, all personal identifications were replaced with surrogate identifications
7
8 suitable for public use and data linkage. The claims data contained information on the
9
10 demographic status of the insured people, dates of treatment and treatments received,
11
12 diagnostic codes, prescriptions, and costs. Diagnosis was coded with the International
13
14 Classification of Disease Diagnoses, 9th Revision of Clinical Modification
15
16 (ICD-9-CM). Several studies in Taiwan in the NHIRD demonstrated the high
17
18 accuracy and validity of ICD-9 diagnosis [18-19]. This study was approved by the
19
20 Research Ethics Committee of China Medical University and Hospital
21
22 (CMUH104-REC2-115).
23
24
25
26
27
28
29
30

31 **Study participants**

32
33
34 Figure 1 shows the flowchart of the subject selection process in this study using a
35
36 population-based retrospective cohort study design. We identified a RA cohort from
37
38 the registry for CIPD and a non-RA cohort from the LHID2000. Patients newly
39
40 diagnosed as having RA (ICD-9-CM 714.0) from 2000 to 2006 and without HL were
41
42 identified for the RA cohort. The date of diagnosis in the catastrophic illness
43
44 certificates was considered as the index date for the approved patients. Patients who
45
46 met four or more of the diagnostic criteria based on the 1987 American College of
47
48 Rheumatology criteria and were newly diagnosed as having RA and those diagnosed
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 by rheumatologists were included in the RA cohort [20]. The application for
5
6 catastrophic illness status was scrutinized by peer review. The patients with RA with a
7
8 catastrophic illness card can be exempted from paying a co-payment.
9
10

11
12 For each patient with RA, four insured people without history of RA and HL
13
14 were randomly selected from the LHID2000 for the non-RA group and were
15
16 frequency-matched by sex, age (each 5-year span), and index year. Individuals with
17
18 missing information on age and/or sex and with history of HL (ICD-9-CM 388.2,
19
20 388.4, 389.00, 389.10, 389.12, 389.2, and 389.9) at baseline were excluded from this
21
22 study.
23
24
25
26
27
28

29 The principal outcome was the development of HL during the follow-up period.
30
31 Both cohorts were followed from the index date to the date of HL diagnosis,
32
33 withdrawal from the NHI system, or the end of 2011. Patients suspected of having HL
34
35 received comprehensive examinations and, subsequently, treatment when the disorder
36
37 was confirmed. In the insurance system, HL patients' medical reimbursement and
38
39 discharge notes are scrutinised by peer review.
40
41
42
43
44
45

46 **Statistical analysis**

47
48

49 Distributions of sex and age (20-39, 40-59, and ≥ 60 years) and baseline
50
51 comorbidities, including diabetes (ICD-9-CM 250), hyperlipidemia (ICD-9-CM 272),
52
53 hypertension (ICD-9-CM 401-405), hyperthyroidism (ICD-9-CM 242), ischemic heart
54
55
56
57
58
59
60

1
2
3
4 disease (IHD; ICD-9-CM 410-414), stroke (ICD-9-CM 430-438), and chronic kidney
5
6 disease (CKD; ICD-9-CM 580-589), between the RA and non-RA cohorts were
7
8 compared. We considered a standardized mean difference of less than 0.1 as a
9
10 negligible difference between two means or two prevalence rates [21]. The incidence
11
12 rate of HL was calculated as the number of incident HL identified during the
13
14 follow-up period divided by the total follow-up person-years for each cohort
15
16 according to sex, age, and each comorbidity. The Kaplan-Meier method was
17
18 employed to plot the cumulative incidence of HL for each cohort during the follow-up
19
20 period, and the log-rank test was used to assess the differences between the two
21
22 curves. Univariate and multivariate Cox proportional hazards regression analyses
23
24 were used to measure the crude hazard ratio (cHR) and adjusted hazard ratio (aHR) of
25
26 HL, respectively, and their 95% confidence intervals (CIs). Sex, age, and
27
28 comorbidities, including diabetes, hyperlipidemia, hypertension, hyperthyroidism,
29
30 IHD, stroke, and CKD, were included as covariates in the multivariate Cox regression
31
32 analysis. To further assess the robustness of our results, we also evaluated the
33
34 association between RA and HL risk in various subgroups by sex, age, and each
35
36 comorbidity.
37
38
39
40
41
42
43
44
45
46
47
48
49

50
51 All analyses were conducted using SAS statistical software (version 9.4 for
52
53 Windows; SAS Institute, Cary, North Carolina, USA), and all statistical tests were
54
55
56
57
58
59
60

1
2
3
4 performed at the two-tailed significance level of 0.05.
5
6
7

8 9 **Results**

10
11
12 In this study, we identified 18,267 RA patients newly diagnosed from 2000 to
13
14 2006 as the RA cohort and 73,068 persons without RA as the non-RA cohort (Table
15
16 1). Distributions of sex, with more women than men (78.4 vs. 21.6%), and age were
17
18 similar between the RA and non-RA cohorts. Approximately 33.3% of the study
19
20 population was ≥ 60 years old. Comorbidities of CKD was more prevalent in patients
21
22 with RA than in subjects without RA at the baseline.
23
24
25
26
27

28
29 The cumulative incidence of HL by the end of follow-up, estimated by the
30
31 Kaplan-Meier method, was 1.5% greater in the RA cohort than in the non-RA cohort
32
33 (3.3 vs. 1.8%; p value < 0.001 in the log-rank test) (Fig. 2). The HL incidence density
34
35 was approximately two-fold greater in the RA cohort than in the non-RA cohort (3.08
36
37 vs. 1.62 per 1000 person-years), with an aHR of 1.89 (95% CI = 1.68-2.12) (Table 2).
38
39 Men were at a greater risk of HL than women, and the risk increased with age.
40
41 Compared to 20–39 years old, the aHRs of HL were 2.72 (95% CI = 2.08-3.57) and
42
43 4.97 (95% CI = 3.77-6.56) for those aged 40-59 and ≥ 60 years, respectively. The risk
44
45 of individuals with comorbidities was also elevated.
46
47
48
49
50
51
52

53
54 Table 3 shows that incidence rates of HL stratified by sex, age, and comorbidity
55
56
57
58
59
60

1
2
3
4 were consistently greater in the RA cohort than in the non-RA cohort. Moreover, men
5
6 had a higher HL incidence than women in both cohorts (i.e., 4.09 per 1000
7
8 person-years in men with RA, which was nearly three-fold greater than that in women
9
10 without RA). Additionally, the HL incidence was greater in patients with each of the
11
12 comorbidities than without it in both cohorts. The excess rate was generally greater in
13
14 patients with RA; those with IHD had the highest incident HL, i.e., 5.60 per 1000
15
16 person-years. The RA cohort to non-RA cohort hazard ratios (HRs) were generally
17
18 similar to the overall HR between the RA and non-RA cohorts (Table 2).
19
20
21
22
23
24
25
26
27
28

29 **Discussion**

30
31
32 This retrospective cohort study showed that patients with RA were nearly two-fold
33
34 more likely to develop HL than the general population (Table 2). In the RA cohort, the
35
36 patients ≥ 60 years old had an HL incidence of 4.92 per 1000 person-years, which was
37
38 greater than that of patients age 20-39 years. The corresponding difference was 2.99 per
39
40 1000 person-years in the non-RA cohort, reflecting the natural HL by aging in the
41
42 general population. The effect of HL associated with RA increased with age. This
43
44 finding is consistent with that of previous studies of patients with SNHL comorbid with
45
46 systemic lupus erythematosus [22] and psoriasis [23]. The risk could increase for 50%
47
48
49
50
51
52
53
54
55
56
57
58
59
60 in patients with psoriasis.

1
2
3
4 Moreover, we found that, in the RA cohort, men had an incidence of 4.09 per
5
6 1000 person-years for HL, which was greater than women had. The corresponding
7
8 difference was 2.24 per 1000 person-years in the non-RA cohort, indicating a greater
9
10 HL effect in men with RA. In the entire study population, the overall aHR was 1.39 in
11
12 men (Table 2). There is a remarkable imbalance between the number of males and
13
14 females with autoimmune diseases, with females representing the majority of cases.
15
16 Although the reasons for this overrepresentation of women are unclear, genetic
17
18 (X-linked) factors and hormonal aspects are likely involved. Halligan et al. [24]
19
20 investigated patients with RA and demonstrated that the prevalence of abnormal
21
22 hearing is significantly greater in males (86% or 12/14) than in females (33% or 5/15)
23
24 ($p = 0.008$). However, no gender difference in hearing impairment among those without
25
26 RA was found ($p = 0.715$).
27
28
29
30
31
32
33
34
35
36

37 In this study, most baseline comorbidities were more prevalent in the RA cohort
38
39 than in controls. Factors associated with RA and the related comorbid chronic diseases
40
41 could be underlying the association between RA and the subsequent development of
42
43 HL. However, the mechanisms underlying the higher HL risk in patients with RA
44
45 remain unclear.
46
47
48
49
50

51 Evidence shows that patients with RA are prevalent with comorbid diseases, such
52
53 as IHD, diabetes, hypertension, and dyslipidemia [25]. The development of RA and the
54
55
56
57
58
59
60

1
2
3
4 breakdown of atherosclerotic plaques possibly have common factors contributing to
5
6 inflammatory cells and proinflammatory cytokines [26]. For example, tumor necrosis
7
8 factor (TNF)- α , an inflammatory cytokine, is involved in the pathogenesis of both RA
9
10 and atherosclerosis [27]. It is possible that both RA and HL have a shared mechanism
11
12 associating with cardiovascular diseases which account for the higher risk of hearing
13
14 loss in patients with RA. Moreover, in this study, we found that patients with RA with
15
16 IHD had the highest HL incidence compared with patients with other cardiovascular
17
18 disorders. Hence, RA and cardiovascular disorders may have a shared contribution to
19
20 HL risk.
21
22
23
24
25
26
27
28

29 Furthermore, several studies [28,29] have reported elevated plasma renin and
30
31 angiotensin-converting enzyme (ACE) activities in patients with RA. Poor blood
32
33 pressure control could induce changes in the renin-angiotensin system. Higher
34
35 oxidative stress in patients with RA could also impair the vasodilatory mechanism of
36
37 the endothelium [29], which could be associated with the higher HL risk in patients
38
39 with RA. Hence, hypertension is likely another risk factor contributing to HL. The
40
41 findings in our study further demonstrate the association between autoimmune disease
42
43 and HL risk.
44
45
46
47
48
49
50

51 The strength of this study is the use of a nationwide population-based cohort to
52
53 identify HL risk in an Asian population with RA. Our findings can be generalized to the
54
55
56
57
58
59
60

1
2
3
4 general population. The large sample size allowed the identification of risk factors
5
6 associated with the development of HL in Taiwan with a minimal tendency for
7
8 selection bias, and enhanced the statistical power and precision of risk appraisal. In
9
10 addition, the inclusion of the CIPD confirmed the diagnoses of all RA cases in the
11
12 NHIRD database, which increased the reliability of our data.
13
14
15

16
17
18 However, several limitations to the interpretation of our findings should be
19
20 considered. Information on several suspected risk factors for HL, such as smoking and
21
22 chronic exposure to occupational and environmental noise, which could be associated
23
24 with HL in the general population, were not available in the insurance database.
25
26 Moreover, information on laboratory test results or HL severity was not available in the
27
28 insurance claims data, and data on RA severity scale, such as disease activity,
29
30 functional impairment, and physical damage, was also unavailable.
31
32
33
34
35

36
37
38 In conclusion, this study provided further evidence of the association between
39
40 autoimmune disease and the development of HL. RA was significantly associated with
41
42 an elevated risk of developing HL, and cardiovascular disorders could increase HL risk.
43
44 Our findings also suggest the need for prompt and early detection of RA for HL
45
46 prevention. Appropriate and timely medical interventions may improve the prognosis of
47
48 hearing loss in patients diagnosed as having RA.
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgments

We would like to thank the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004); China Medical University Hospital; Academia Sinica Taiwan Biobank, Stroke Biosignature Project (BM10501010037); NRPB Stroke Clinical Trial Consortium (MOST 105-2325-B-039-003); Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan, for their support.

Conflict of interest: None.

Footnotes:

Contributors: C-MH and F-CS conceived and designed the study. C-MH wrote the manuscript and revised the important intellectual content. Data were analysed by F-CS and H-JC. F-CS revised important intellectual content and was responsible for the final version of the manuscript. Conception and design summary: C-MH, P-HH, GJT and J-LL. All authors read and approved the final manuscript.

Competing interests: None declared.

Provenance and peer review: Not commissioned; externally peer reviewed.

1
2
3
4 **Data sharing statement:** No additional data are available.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References:

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. *Cell* 1996;85:307-310.
2. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. *N Engl J Med* 1990;322:1277-1289.
3. Ozcan M, Karakus MF, Gunduz OH, Tuncel U, Sahin H. Hearing loss and middle ear involvement in rheumatoid arthritis. *Rheumatol Int* 2002;22:16–19.
4. Murdin L, Patel S, Walmsley J, Yeoh LH. Hearing difficulties are common in patients with rheumatoid arthritis. *Clin Rheumatol* 2008;27:637–640.
5. Halligan CS, Bauch CD, Brey RH, Achenbach SJ, Bamlet WR, McDonald TJ, et al. Hearing loss in rheumatoid arthritis. *Laryngoscope* 2006;116:2044–2049.
6. Takatsu M, Higaki M, Kinoshita H, Mizushima Y, Koizuka I. Ear involvement in patients with rheumatoid arthritis. *Otol Neurotol* 2005;26:755–761.
7. Elwany S, Garf A, Kamel T. Hearing and middle ear function in rheumatoid arthritis. *J Rheumatol* 1986;13:878–881.
8. Magaro M, Zoli A, Altomonte Z, Mirone L, Corvino G, Di Girolamo S, et al. Sensorineural hearing loss in rheumatoid arthritis. *Clin Exp Rheum* 1990;8:487–490.

- 1
2
3
4 9. Takatsu M, Higaki M, Kinoshita H, Mizushima Y, Koizuka I. Ear involvement in
5
6 patients with rheumatoid arthritis. *Otol Neurotol* 2005;26:755–761.
7
8
- 9
10 10. Salvinelli F, Cancilleri F, Casale M, Luccarelli V, Di Peco V, D’Ascanio L, et al.
11
12 Hearing thresholds in patients affected by rheumatoid arthritis. *Clin Otolaryngol*
13
14 2014;29:75–79.
15
16
- 17
18 11. Pascual-Ramos V, Contreras-Yáñez I, Rivera-Hoyos P, Enríquez L,
19
20 Ramírez-Anguiano J. Cumulative disease activity predicts incidental hearing
21
22 impairment in patients with rheumatoid arthritis (RA). *Clin Rheumatol* 2014; 33(3):
23
24 315–321.
25
26
27
- 28
29 12. Takatsu M, Higaki M, Kinoshita H, Mizushima Y, Koizuka I. Ear involvement in
30
31 patients with rheumatoid arthritis. *Otol Neurotol* 2005;26(4):755–761.
32
33
- 34
35 13. Murdin L, Patel S, Walmsley J, Yeoh LH. Hearing difficulties are common in
36
37 patients with rheumatoid arthritis. *Clin Rheumatol* 2008;27(5):637–640.
38
39
- 40
41 14. Bayazit YA, Yilmaz M, Gunduz B, Altinyay S, Kemaloglu YK, Onder M, et al.
42
43 Distortion product otoacoustic emission findings in Behçet’s disease and
44
45 rheumatoid arthritis. *ORL J Otorhinolaryngol Relat Spec* 2007;69(4):233–238.
46
47
- 48
49 15. Mijovic T, Zeitouni A, Colmegna I. Autoimmune sensorineural hearing loss: the
50
51 otology-rheumatology interface. *Rheumatology (Oxford)* 2013;52:780–789.
52
53
54
55
56
57
58
59

- 1
2
3
4 16. Ozturk A, Yalcin S, Kaygusuz I, Sahin S, Gok U, Karlidag T, et al. High-frequency
5
6 hearing loss and middle ear involvement in rheumatoid arthritis. *Am J Otolaryngol*
7
8
9 2014;25:411–417.
10
11
12 17. Cheng SH, Chen CC, Tsai SL. The impacts of DRG-based payments on health care
13
14 provider behaviors under a universal coverage system: a population-based study.
15
16 *Health Policy* 2012;107:202–208.
17
18
19 18. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health
20
21 Insurance Research Database with ischemic stroke cases in Taiwan.
22
23 *Pharmacoepidemiol Drug Saf* 2011;20:236–242.
24
25
26
27
28 19. Yu YB, Gau JP, Liu CY, Yang MH, Chiang SC, Hsu HC, et al. A nation-wide
29
30 analysis of venous thromboembolism in 497 180 cancer patients with the
31
32 development and validation of a risk-stratification scoring system. *Thromb*
33
34 *Haemost* 2012;108:225–235.
35
36
37
38
39 20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The
40
41 American Rheumatism Association 1987 revised criteria for the classification of
42
43 rheumatoid arthritis. *Arthritis Rheum* 1988;3:315–324.
44
45
46
47
48 21. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, et al.
49
50 Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for
51
52 confounding. *BMJ* 2005; 330: 960–2.
53
54
55
56
57
58
59
60

- 1
2
3
4 22. Lin C, Lin SW, Weng SF, Lin YS. Risk of sudden sensorineural hearing loss in
5
6 patients with systemic lupus erythematosus: a population-based cohort study.
7
8 Audiol Neurotol 2013;18(2):95–100.
9
10
11
12 23. Yen YC, Lin YS, Weng SF, Lai FJ. Risk of sudden sensorineural hearing loss in
13
14 patients with psoriasis: a retrospective cohort study. Am J Clin Dermatol
15
16 2015;16(3):213–220.
17
18
19
20 24. Halligan CS, Bauch CD, Brey RH, Achenbach SJ, Bamlet WR, McDonald TJ, et al.
21
22 Hearing loss in rheumatoid arthritis. Laryngoscope 2006;116(11):2044–2049.
23
24
25
26 25. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al.
27
28 Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is
29
30 associated with coronary atherosclerosis. Atherosclerosis 2008;196(2):756–763.
31
32
33
34 26. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost
35
36 2009;7(Suppl 1):328–331.
37
38
39
40 27. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid
41
42 arthritis. Am J Med 2008;121:S21–31.
43
44
45
46 28. Samoriadova OS, Zharova EA, Masenko VP, Balabanova RM, Vil'chinskaia MIu,
47
48 Nasonov EL. The renin-angiotensin-aldosterone system and arterial hypertension in
49
50 patients with rheumatoid arthritis. Klin Med (Mosk). 1991;69(2):69–71.
51
52
53
54 29. Sakuta T, Morita Y, Satoh M, Fox DA, Kashihara N. Involvement of the
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

renin-angiotensin system in the development of vascular damage in a rat model of
arthritis: effect of angiotensin receptor blockers. Arthritis Rheum 2010;62(5):1319–
1328.

For peer review only

Table 1. Distribution of demographic factors and comorbidity between cohorts

Variable	Non-RA cohort N = 73,068		RA cohort N = 18,267		Standardized mean difference
	n	%	n	%	
Sex					
Female	57,288	78.4	14322	78.4	<0.001
Male	15,780	21.6	3945	21.6	<0.001
Age, years					
20-39	12,224	16.7	3056	16.7	<0.001
40-59	36,532	50.0	9133	50.0	<0.001
≥ 60	24,312	33.3	6078	33.3	<0.001
Means (SD)	53.3	(14.2)	53.6	(13.9)	0.021
Comorbidity					
DM	8102	11.1	2114	11.6	0.015
Hyperlipidemia	14,078	19.3	3439	18.8	0.011
Hypertension	22,844	31.3	5964	32.7	0.030
Hyperthyroidism	1089	1.49	456	2.50	0.072
IHD	10,993	15.0	2941	16.1	0.029
Stroke	2128	2.91	483	2.64	0.016
CKD	4821	6.60	2061	11.3	0.165

Abbreviation: RA, rheumatoid arthritis; SD, standard deviation; DM, diabetes mellitus; IHD, ischemic heart disease; CKD, chronic kidney disease.

Table 2. Cox model measured hazard ratios and 95% confidence intervals of hearing loss associated with rheumatoid arthritis and covariates

Variables	Event no.	Person-years	IR	HR (95% CI)	
				Univariate	Multivariate [‡]
RA					
No	927	572031	1.62	1.00	1.00
Yes	429	139085	3.08	1.90 (1.70-2.13)	1.89 (1.68-2.12)
Sex					
Female	977	565205	1.73	1.00	1.00
Male	379	145912	2.60	1.49 (1.33-1.68)	1.39 (1.23-1.56)
Age, years					
20-39	59	123836	0.48	1.00	1.00
40-59	563	368175	1.53	3.21 (2.45-4.19)	2.72 (2.08-3.57)
≥ 60	734	219105	3.35	6.98 (5.35-9.10)	4.97 (3.77-6.56)
Comorbidity [†]					
No	469	405253	1.16	1.00	1.00
Yes	887	305864	2.90	2.49 (2.23-2.79)	1.66 (1.47-1.87)

Abbreviation: IR, incidence rates per 1000 person-years; HR, hazard ratio; CI, confidence interval; RA, rheumatoid arthritis; DM, diabetes mellitus; IHD, ischemic heart disease; CKD, chronic kidney disease.

[†]Patients with DM, hyperlipidemia, hypertension, hyperthyroidism, IHD, stroke, and CKD dermatitis were classified as the comorbidity group.

[‡]Multivariate Cox proportional hazards regression model, including RA, sex, age, and comorbidity.

Table 3. Incidence rates and hazard ratios of hearing loss by sex, age, and comorbidity in the two cohorts

Variables	Non-RA cohort			RA cohort			RA cohort to non-RA cohort	
	Event no.	Person-years	IR	Event no.	Person-years	IR	HR (95% CI)	
							Crude	Adjusted [†]
Sex								
Women	663	454249	1.46	314	110956	2.83	1.94 (1.69-2.22)	1.96 (1.71-2.24)
Men	264	117782	2.24	115	28130	4.09	1.82 (1.46-2.27)	1.86 (1.49-2.32)
Age, years								
20-39	40	98817	0.40	19	25020	0.76	1.89 (1.09-3.26)	1.91 (1.10-3.32)
40-59	355	295193	1.20	208	72982	2.85	2.37 (2.00-2.81)	2.33 (1.96-2.76)
≥ 60	532	178021	2.99	202	41084	4.92	1.63 (1.39-1.92)	1.63 (1.38-1.91)
Comorbidity								
DM								
No	765	514262	1.49	362	124722	2.90	1.95 (1.72-2.21)	1.95 (1.72-2.21)
Yes	162	57770	2.80	67	14363	4.66	1.66 (1.25-2.21)	1.75 (1.31-2.33)
Hyperlipidemia								
No	654	464753	1.41	320	113890	2.81	2.00 (1.75-2.28)	1.97 (1.72-2.25)
Yes	273	107279	2.54	109	25195	4.33	1.69 (1.36-2.11)	1.76 (1.41-2.20)
Hypertension								
No	481	402716	1.19	233	97031	2.40	2.01 (1.72-2.35)	1.97 (1.68-2.30)
Yes	446	169316	2.63	196	42054	4.66	1.76 (1.49-2.08)	1.82 (1.54-2.16)
Hyperthyroidism								

	No	909	563891	1.61	416	135733	3.06	1.90 (1.69-2.13)	1.93 (1.72-2.17)
	Yes	18	8140	2.21	13	3352	3.88	1.76 (0.86-3.58)	1.76 (0.86-3.63)
	IHD								
	No	671	491566	1.37	316	118909	2.66	1.95 (1.70-2.23)	1.98 (1.73-2.26)
	Yes	256	80466	3.18	113	20176	5.60	1.75 (1.40-2.18)	1.75 (1.40-2.19)
	Stroke								
	No	896	559458	1.60	414	136197	3.04	1.90 (1.69-2.13)	1.91 (1.70-2.15)
	Yes	31	12573	2.47	15	2888	5.19	2.10 (1.13-3.89)	2.16 (1.14-4.06)
	CKD								
	No	835	538065	1.55	369	124534	2.96	1.91 (1.69-2.16)	1.95 (1.73-2.21)
	Yes	92	33967	2.71	60	14551	4.12	1.53 (1.11-2.12)	1.73 (1.24-2.41)

Abbreviation: RA, rheumatoid arthritis; IR, incidence rates per 1000 person-years; HR, hazard ratio; CI, confidence interval.

[†] Model mutually adjusted for sex, age, DM, hyperlipidemia, hypertension, hyperthyroidism, IHD, stroke, and CKD in Cox proportional hazards regression.





Fig 1. Flowchart showing selection of study cohorts

LHID, Longitudinal Health Insurance Database; RA, rheumatoid arthritis



32 No. at risk

34 Non-RA group	73068	70979	68952	56187	35795	16093
36 RA group	18267	17445	16643	13564	8541	3836

37
38
39
40 Fig 2. Kaplan-Meier method estimated Cumulative incidence curves of hearing loss in
41 the two cohorts
42
43 RA, rheumatoid arthritis
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement

Checklist of items that should be included in reports of observational studies

Section/Topic	Item No	Recommendation	Reported on Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6,7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7,8
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
Variables	7	(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	7,8
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Data sources/measurement	8*	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Bias	9	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8
Study size	10	Describe any efforts to address potential sources of bias	8
Quantitative variables	11	Explain how the study size was arrived at	7,8
Statistical methods	12	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7,8
		(a) Describe all statistical methods, including those used to control for confounding	8,9
		(b) Describe any methods used to examine subgroups and interactions	8,9
		(c) Explain how missing data were addressed	26
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	26
<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed			
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	9
		(e) Describe any sensitivity analyses	9

Section/Topic	Item No	Recommendation	Reported on Page No
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	26
		(c) Consider use of a flow diagram	26
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10,22
		(b) Indicate number of participants with missing data for each variable of interest	26
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10,27
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10,27
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10,23
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10,11,24
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	13,14
Other Information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Retrospective Cohort Study on Risk of Hearing Loss in Patients with Rheumatoid Arthritis Using Claims Data

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018134.R1
Article Type:	Research
Date Submitted by the Author:	29-Aug-2017
Complete List of Authors:	Huang, Chung-Ming Chen, Hsuan-Ju; China Medical University Hospital Huang, Po-Hao Tsay, Gregory J Lan, Joung-Liang Sung, Fung-Chang
Primary Subject Heading:	Rheumatology
Secondary Subject Heading:	Epidemiology, Ear, nose and throat/otolaryngology
Keywords:	Rheumatoid arthritis, hearing loss, insurance data,, retrospective cohort study

SCHOLARONE™
Manuscripts

Retrospective Cohort Study on Risk of Hearing Loss in

Patients with Rheumatoid Arthritis Using Claims Data

Chung-Ming Huang^{1,2}, Hsuan-Ju Chen^{3,4}, Po-Hao Huang¹, Gregory J Tsay¹,
Joung-Liang Lan¹, Fung-Chang Sung^{3,5}

Running Title: Hearing loss in rheumatoid arthritis

¹Division of Immunology and Rheumatology, Department of Internal Medicine,
China Medical University Hospital, Taichung, Taiwan;

²Graduate Institute of Integrated Medicine, College of Chinese Medicine, China
Medical University, Taichung, Taiwan

³Management Office for Health Data, China Medical University Hospital, Taichung,
Taiwan

⁴College of Medicine, China Medical University, Taichung, Taiwan

⁵Department of Health Services Administration, China Medical University, Taichung,
Taiwan

Corresponding author:

Fung-Chang Sung, PhD, MPH
Department of Health Services Administration, China Medical University
91 Hsueh Shih Road
Taichung 404, Taiwan
Tel: 886-4-2205-4070
Fax: 886-4-2233-9216
E-mail: fcsung1008@yahoo.com

Word count: Abstract 247; Strength and limitation 145; Text 2603; 4 Tables; 2
Figures.

ABSTRACT

Purposes:

Hearing loss (HL) has been reported as a manifestation of systemic vascular involvement in patients with an autoimmune disease. However, population studies on HL associated with rheumatoid arthritis (RA) are lacking. This study investigated the risk of developing HL in patients with RA using a nationwide population cohort.

Participants:

We used the Taiwan National Health Insurance Research Database to identify 18,267 RA patients newly diagnosed in 2000-2006 and 73,068 controls without RA, frequency-matched by sex, age, and index year. We estimated HL incidences in both cohorts and the RA cohort to non-RA cohort hazard ratios (HRs) after adjusting for sex, age, and comorbidities by the end of 2011.

Findings to date:

The HL incidence was higher in the RA cohort than in the non-RA cohort (3.08 versus 1.62 per 1000 person-years), with an adjusted HR of 1.91 (95% confidence interval = 1.70-2.14) for the RA cohort relative to the non-RA cohort after controlling for age, sex, and comorbidities. Men and the elderly are at a higher risk.

1
2
3
4 Cardiovascular comorbidities were associated with a further increased HL risk for RA
5
6 patients. Medications were associated with reduced HL incidence; RA patients who
7
8 used NSAIDs had an aHR of 0.12 (95% CI = 0.07-0.20), compared with non-users.
9
10

11
12
13 **Conclusions:**
14

15
16
17 This population-based retrospective cohort study demonstrates that patients with RA
18
19 are at an increased risk of developing HL. Adequate medications should be provided
20
21 to patients with RA diagnosed and scheduled auditory examinations should be
22
23 available to enable the early detection of HL.
24
25
26

27
28
29 **Keywords:** Rheumatoid arthritis, hearing loss, insurance data, retrospective cohort
30
31 study
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strength and limitation of this study

1. The strength of this study is the use of a nationwide population-based cohort to identify HL risk in an Asian population with RA. Our findings can be generalized to the general population.
2. The inclusion of the Catastrophic Illness Patient Database confirmed the diagnoses of all RA cases with increased the reliability of our data; the large sample size reduced the tendency for selection bias, enhanced statistical power and precision of risk appraisal.
3. Some limitations in this study should be considered. Information on several suspected risk factors for HL, such as smoking and chronic exposure to occupational and environmental noise, which could be associated with HL in the general population, were not available in the insurance database.
4. Information on laboratory test results and HL severity, and on RA severity scale, such as disease activity, functional impairment and physical damage was also unavailable.

Introduction

Rheumatoid arthritis (RA) is a disease predominantly characterized by chronic joint inflammation and is often accompanied by several peripheral inflammatory manifestations [1]. RA may lead to the destruction of the cartilage and bone due to chronic synovitis and may consequently impair joint function [2]. In addition, patients with RA may have extra-articular manifestations involving other organ systems [3], such as auditory system alteration, although with a different putative mechanism of damage [4–6]. With respect to the auditory system, previous studies have shown conflicting findings, in both types of hearing loss, and the RA disease activity and severity [7-10].

There are a wide variations in the reported prevalence of hearing loss in patients with RA. Sensorineural hearing loss (SNHL) is the most common hearing impairment in patients with RA, ranging from 25 to 72% [11], whereas conductive hearing loss and mixed hearing loss are less frequently reported [4,6,12]. SNHL could be induced by a direct immune response of either T or B cells against inner ear proteins [13].

Neurovascular inflammation and drugs used for RA treatment could also damage the cochlea [14]. Thus, hearing loss (HL) may be a manifestation of systemic vascular involvement in patients with RA and may have a significant effect on the health of patients with RA. However, the risk of developing HL in patients with RA has not

1
2
3
4 been well examined using population data.
5

6 Hence, the purpose of this study was to investigate the risk of HL in patients with
7
8
9 RA, using representative insurance claims data obtained from the Taiwan National
10
11
12 Health Insurance (NHI). The HL risk associated with other comorbidities, such as
13
14
15 coronary heart disease, hypertension, stroke, diabetes, hyperlipidemia,
16
17
18 hyperthyroidism, hypothyroidism, chronic renal disease and autoimmune diseases,
19
20
21 were also evaluated.
22
23
24
25

26 **Materials and Methods**

27 **Data source**

28
29
30
31 The Taiwan NHI system is a single-payer compulsory programme with a
32
33
34 coverage of over 99% of 23.74 million people [15]. We conducted this study using
35
36
37 two data sets: the Registry for Catastrophic Illness Patient Database (CIPD) and the
38
39
40 Longitudinal Health Insurance Database (LHID2000), obtained from the Taiwan
41
42
43 National Health Research Institutes. Patients with major diseases, such as cancer,
44
45
46 chronic mental illness, end-stage renal disease and several autoimmune diseases
47
48
49 requiring long-term care are eligible for the CIPD coverage for exemption from
50
51
52 making co-payment. The LHID2000 contains the claims data of 1,000,000 people
53
54
55 randomly sampled from all populations being registered in 2000 for the insurance
56
57
58
59
60

1
2
3
4 coverage. Reimbursement claims data for medical services from 1996 to 2011 in both
5
6 data sets were used in this study. For privacy protection, all personal identifications
7
8 were replaced with surrogate identifications suitable for public use and data linkage.
9
10
11 The claims data contained information on the demographic status of the insured
12
13 people, dates of treatment and treatments received, diagnostic codes, prescriptions,
14
15 and costs. Diagnoses of diseases were coded with the International Classification of
16
17 Disease Diagnoses, 9th Revision of Clinical Modification (ICD-9-CM). Several
18
19 studies in Taiwan using the insurance claims data have demonstrated high accuracy
20
21 and validity of ICD-9 diagnosis [16-17]. This study was approved by the Research
22
23 Ethics Committee of China Medical University and Hospital (CMUH104-REC2-115).
24
25
26
27
28
29
30

31 **Study population**

32
33
34 Figure 1 shows the flowchart for identifying and selecting study population using
35
36 a population-based retrospective cohort study design. We identified a RA cohort from
37
38 the registry for CIPD and a non-RA cohort from the LHID2000. Patients newly
39
40 diagnosed with RA (ICD-9-CM 714.0) from 2000 to 2006 and without HL were
41
42 included in the RA cohort. The date with RA certificated as the catastrophic illness
43
44 was considered as the index date for the approved patients. Patients who met four or
45
46 more of the diagnostic criteria based on the 1987 American College of Rheumatology
47
48 criteria were considered as having RA and those diagnosed by rheumatologists were
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 included in the RA cohort [18]. The application for catastrophic illness status was
4
5
6 scrutinized by peer review.
7

8
9 For each patient with RA, four insured people without history of RA and HL
10
11 were randomly selected from the LHID2000 for the non-RA cohort and were
12
13 frequency-matched by sex, age (each 5-year span), and index year. Individuals with
14
15 missing information on age and/or sex or with history of HL (ICD-9-CM 388.2, 388.4,
16
17 389.00, 389.10, 389.12, 389.2, and 389.9) at baseline were excluded from the non-RA
18
19 cohort.
20
21
22
23
24

25
26 Both cohorts were followed from the index date to the date with HL diagnosed,
27
28 withdrawal from the NHI system, or the end of 2011. In general, HL was diagnosed
29
30 based on the audiometry test. To increase the validity of HL diagnosis, only patients
31
32 with three or more diagnoses in outpatient claims or an inpatient record were included
33
34 in the study. Patients who were suspected of having HL received comprehensive
35
36 examinations and, subsequently, treatment was followed when the disorder was
37
38 confirmed. In the insurance system, HL patients' medical reimbursement and
39
40 discharge notes are scrutinised by peer review. The insurance system also randomly
41
42 reviewed insurance claims to prevent errors and violations. Therefore, diagnoses and
43
44 codes of HL in the study were highly reliable. [16]
45
46
47
48
49
50
51
52

53 54 **Statistical analysis**

55
56
57
58
59
60

1
2
3
4 Distributions of sex and age (20-39, 40-59, and ≥ 60 years) and baseline
5
6 comorbidities, including diabetes (ICD-9-CM 250), hyperlipidemia (ICD-9-CM 272),
7
8 hypertension (ICD-9-CM 401-405), hyperthyroidism (ICD-9-CM 242), ischemic heart
9
10 disease (IHD; ICD-9-CM 410-414), stroke (ICD-9-CM 430-438), chronic kidney
11
12 disease (CKD; ICD-9-CM 580-589), hypothyroidism (ICD-9-CM 244), and
13
14 autoimmune diseases (including psoriasis [ICD-9-CM 696], systemic lupus
15
16 erythematosus [ICD-9-CM 710.0], systemic sclerosis [ICD-9-CM 710.1], Sjogren
17
18 syndrome [ICD-9-CM 710.2], dermatomyositis [ICD-9-CM 710.3], polymyositis
19
20 [ICD-9-CM 710.4], and vasculitis [ICD-9-CM 446.0, 446.2, 446.4, 446.5, 443.1,
21
22 446.7, 446.1, and 136.1]), between the RA and non-RA cohorts were compared. A
23
24 standardized mean difference of less than 0.1 was a negligible difference between two
25
26 means or two prevalence rates [19]. The incidence density of HL per 1000
27
28 person-years was calculated during the follow-up period by sex, age and comorbidity.
29
30 The Kaplan-Meier method was employed to plot the cumulative incidence of HL for
31
32 each cohort during the follow-up period, and the log-rank test was used to assess the
33
34 differences between the two curves. Univariate and multivariate Cox proportional
35
36 hazards regression analyses were used to measure the RA cohort to non-RA cohort
37
38 crude hazard ratio (cHR) and adjusted hazard ratio (aHR) of HL, respectively, and
39
40 their 95% confidence intervals (CIs). Sex, age, and comorbidities including diabetes,
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 hyperlipidemia, hypertension, hyperthyroidism, hypothyroidism, IHD, stroke, CKD
5
6 and autoimmune diseases, were included as covariates in the multivariate Cox
7
8 regression analysis. To further assess the robustness of our results, we also evaluated
9
10 the association between RA and HL risk in various subgroups by sex, age, and each
11
12 comorbidity. We further evaluated the treatment effectiveness of medications for RA
13
14 patients by calculating the incidence density and HRs of HL. Medications that had
15
16 been prescribed for RA treatment during the follow-up period included Nonsteroidal
17
18 anti-inflammatory drugs (NSAIDs), prednisolone, disease-modifying antirheumatic
19
20 drugs (DMARDs, including hydroxychloroquine, sulfasalazine, methotrexate, and
21
22 leflunomide), and tumor necrosis factor (TNF, including etanercept and adalimumab).
23
24
25
26
27
28
29
30

31
32 All analyses were conducted using SAS statistical software (version 9.4 for
33
34 Windows; SAS Institute, Cary, North Carolina, USA), and all statistical tests were
35
36 performed at the two-tailed significance level of 0.05.
37
38
39
40
41
42

43 **Results**

44
45
46 We identified 18,267 RA patients newly diagnosed from 2000 to 2006 for the
47
48 RA cohort and 73,068 persons without RA for the non-RA cohort as controls (Table
49
50 1). There were more women than men (78.4 vs. 21.6%) in both cohorts.
51
52
53
54 Approximately 66.7% of the study populations were <60 years old. Prevalence rates
55
56
57
58
59
60

1
2
3
4 of CKD and autoimmune diseases were more prevalent in patients with RA than in
5
6 controls at the baseline.
7

8
9 The Kaplan-Meier method estimated cumulative incidence of HL was 1.5%
10
11 greater in the RA cohort than in the non-RA cohort (3.3 vs. 1.8%; p value < 0.001 in
12
13 the log-rank test) (Fig. 2). The incidence density of HL was approximately two-fold
14
15 greater in the RA cohort than in the non-RA cohort (3.08 vs. 1.62 per 1000
16
17 person-years), with an aHR of 1.91 (95% CI = 1.70-2.14) (Table 2). Men were at a
18
19 greater risk of HL than women, and the risk increased with age. Compared to 20–39
20
21 years old, the aHRs of HL were 2.89 (95% CI = 2.21-3.79) and 5.27 (95% CI =
22
23 3.99-6.95) for those aged 40-59 and those aged ≥ 60 years, respectively. The HL risk
24
25 for individuals with comorbidities was also elevated. Patients with hypertension and
26
27 IHD were significantly associated with higher risk of HL compared with their
28
29 counterparts without the disorder, with aHRs of 1.21 (95% CI = 1.07-1.38) and of
30
31 1.36 (95% CI = 1.19-1.56), respectively.
32
33
34
35
36
37
38
39
40
41
42

43 Table 3 shows that incidence rates of HL stratified by sex, age, and comorbidity
44
45 were consistently greater in the RA cohort than in the non-RA cohort. Comorbidity
46
47 was associated with further increased HL risk for RA patients. RA patients with IHD
48
49 had the highest incident HL, 5.60 per 1000 person-years.
50
51
52

53
54 Table 4 shows that medications were associated with reduced incident HL for RA
55
56
57
58
59
60

1
2
3 patients. Near 99% of RA patients used NSAIDs and users had a HL incidence of 2.98
4
5
6 per 1000 person-years, with an aHR of 0.12 (95% CI = 0.07-0.20) compared with
7
8
9 non-users who had an incidence of 30.1 per 1000 person-years for HL. RA patients on
10
11 medications of TNF (n = 2706) had the lowest HL incidence of 1.17 per 1000
12
13 person-years with an aHR of 0.40 (95% CI = 0.27-0.59), compared with non-users
14
15 who had an incidence of 3.45 per 1000 person-years.
16
17
18
19
20
21
22

23 Discussion

24
25
26 This retrospective cohort study showed that patients with RA were nearly two-fold
27
28 more likely to develop HL than those without RA. The risk of HL associated with RA
29
30 increased with age. In the RA cohort, those ≥ 60 years old had an HL incidence of 4.92
31
32 per 1000 person-years, which was 4.16 per 1000 person-year greater than that of
33
34 patients aged 20-39 years. The corresponding difference was 2.49 per 1000
35
36 person-years between the 2 age groups in the non-RA cohort, reflecting the natural HL
37
38 by aging in the non-RA cohort. Similar to reports in other studies, HL is age dependent
39
40 in patients and control subjects [6, 14, 20]. This finding is also consistent with previous
41
42 studies for patients with sudden sensorineural hearing loss comorbid with systemic
43
44 lupus erythematosus [21] and psoriasis [22]. The excess HL risk could be 50% in
45
46 patients with psoriasis.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 We also found that, in the RA cohort, men had an incidence of 4.09 per 1000
5
6 person-years for HL, which was 1.26 per 1000 person-years greater than women had.
7
8
9 The corresponding difference was 0.78 per 1000 person-years in the non-RA cohort,
10
11 indicating the relationship between RA and HL risk may be slightly greater for men. In
12
13 the entire study population, the overall aHR was 1.40 for men compared with women
14
15 (Table 2). There is a remarkable imbalance between the number of males and females
16
17 with autoimmune diseases, with females representing the majority of cases. Although
18
19 reasons for this overrepresentation of women are unclear, genetic (X-linked) factors and
20
21 hormonal aspects are likely involved. Halligan et al. [23] investigated patients with RA
22
23 and also demonstrated that the prevalence of abnormal hearing is significantly greater
24
25 in males (86% or 12/14) than in females (33% or 5/15) ($p = 0.008$). However, no
26
27 significant gender difference in HL among those without RA was found ($p = 0.715$).
28
29
30
31
32
33
34
35
36

37 Evidences have shown that patients with RA are prevalent with comorbidities, such
38
39 as IHD [24-26], stroke [27], hypertension [28,29], diabetes [30-32], dyslipidemia
40
41 [27,33], CKD [34,35] and thyroid disorders [36-38]. In this study, the study populations
42
43 in both cohorts were young. The baseline prevalence rates of most comorbidities
44
45 between the 2 cohorts were not significantly different, except that CKD and
46
47 autoimmune diseases were more prevalent in patients with RA than in controls without
48
49 RA at the baseline (Table 1). However, it is interest to note that most of the
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 comorbidities are associated with further increased incidence of HL, greater for the RA
5
6 cohort than for the non-RA cohort, except hypothyroidism, and autoimmune diseases
7
8
9 (Table 3).
10

11
12 The development of RA and the breakdown of atherosclerotic plaques possibly
13
14 share common factors contributing to inflammatory cells and pro-inflammatory
15
16 cytokines [25]. Pro-inflammatory cytokines may contribute to the oxidative damage in
17
18 the inner ear [26]. For example, both tumor necrosis factor (TNF)- α and interleukin
19
20 (IL)-6 are involved in the pathogenesis of both RA and atherosclerosis [39]. However,
21
22 Takatsu et al. [6] showed that the pro-inflammatory cytokines (IL-6) and matrix
23
24 metalloproteinase (MMP) -3 may contribute to harm inner ear cells by an oxidative
25
26 process. Both RA and HL may have a shared mechanism associating with
27
28 cardiovascular diseases which account for the higher risk of hearing loss in patients
29
30 with RA. IHD alone may associate with HL. An earlier study found patients with IHD
31
32 are prevalent with HL for up to over 30% [40]. Moreover, in this study, we found that
33
34 patients with RA with IHD had the highest HL incidence among patients with
35
36 cardiovascular disorders. Hence, RA and cardiovascular disorders may have a shared
37
38 contribution to HL risk.
39
40
41
42
43
44
45
46
47
48
49

50
51 Furthermore, several studies [41,42] have reported elevated plasma renin and
52
53 angiotensin-converting enzyme (ACE) activities in patients with RA. Poor blood
54
55
56
57
58
59

1
2
3
4 pressure control could induce changes in the renin-angiotensin system. Higher
5
6 oxidative stress in patients with RA could also impair the vasodilatory mechanism of
7
8 the endothelium [42], which could be associated with the higher HL risk in patients
9
10 with RA. Hence, hypertension is likely another risk factor contributing to HL. The
11
12 findings in our study further demonstrate the association between autoimmune disease
13
14 and HL risk.
15
16
17
18
19

20
21 After adjustment for sex, age, and comorbidity, we found reduced HL risk for
22
23 RA patients on medication of NSAID, prednisolone, DMARDs and TNF. Conversely,
24
25 Halligan et al. [23] described an association between HL and hydroxychloroquine, and
26
27 Dikici et al. [43] observed a dose relation between HL using methotrexate. On the other
28
29 hand, some studies found no relationship between HL and RA treatment using NSAID,
30
31 corticosteroid and DMARDs [6, 9, 20, 44]. The inconsistent results may be due to the
32
33 relatively small study sample sizes, while our study is a nationwide population-based
34
35 cohort with large sample size. It is likely, the reduced inflammation in patients with RA
36
37 on medications of NSAID, corticosteroid, DMARDs and TNF could be associated with
38
39 reduce the HL risk.
40
41
42
43
44
45
46
47
48

49 The strength of this study is the use of a nationwide population-based cohort to
50
51 evaluate HL risk in an Asian population with RA. Our findings can be generalized to
52
53 the general population. The large sample size allowed the identification of risk factors
54
55
56
57
58
59
60

1
2
3
4 associated with the development of HL in Taiwan with a minimal tendency for
5
6 selection bias, and enhanced the statistical power and precision of risk appraisal. In
7
8 addition, the inclusion of the CIPD confirmed the diagnoses of all RA cases in the
9
10 NHIRD database, which increased the reliability of our data.
11
12
13
14

15 However, several limitations to the interpretation of our findings should be
16
17 considered. Information on several suspected risk factors for HL was unavailable, such
18
19 as smoking and chronic exposure to occupational and environmental noise, which could
20
21 be associated with HL for both cohorts. Moreover, information on laboratory test
22
23 results, HL severity, and RA severity scale and activity, functional impairment and
24
25 physical damage of the disease was also unavailable.
26
27
28
29
30
31

32 In conclusion, this study demonstrated that patients with RA are at an elevated
33
34 risk of developing HL. Our findings also suggest the need for prompt and early
35
36 detection of RA for HL prevention. Appropriate and timely medical interventions may
37
38 improve the prognosis of hearing loss for patients diagnosed with RA.
39
40
41
42
43
44
45

46 **Acknowledgments**

47
48

49 We would like to thank the Taiwan Ministry of Health and Welfare Clinical Trial
50
51 and Research Center of Excellence (MOHW106-TDU-B-212-113004); China Medical
52
53 University Hospital; Academia Sinica Taiwan Biobank, Stroke Biosignature Project
54
55
56
57
58
59
60

1
2
3
4 (BM10601010036); Taiwan Clinical Trial Consortium for Stroke (MOST
5
6 106-2321-B-039-005); Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain
7
8
9 Disease Foundation, Taipei, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds,
10
11
12 Japan, for their support.
13

14
15
16
17
18 **Conflict of interest:** None.
19

20
21
22
23 **Footnotes:**

24
25
26 **Contributors:** C-MH and F-CS conceived and designed the study. C-MH wrote the
27
28 manuscript and revised the important intellectual content. Data were analyzed by F-CS
29
30 and H-JC. F-CS revised important intellectual content and was responsible for the final
31
32 version of the manuscript. Conception and design summary: C-MH, P-HH, GJT and
33
34 J-LL. All authors read and approved the final manuscript.
35
36
37
38

39
40 **Competing interests:** None declared.
41

42
43 **Provenance and peer review:** Not commissioned; externally peer reviewed.
44

45
46 **Data sharing statement:** No additional data are available.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. *Lancet* 2010;376:1094–1098.
2. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. *N Engl J Med* 1990;322:1277-1289.
3. Ozcan M, Karakus MF, Gunduz OH, Tuncel U, Sahin H. Hearing loss and middle ear involvement in rheumatoid arthritis. *Rheumatol Int* 2002;22:16–19.
4. Murdin L, Patel S, Walmsley J, Yeoh LH. Hearing difficulties are common in patients with rheumatoid arthritis. *Clin Rheumatol* 2008;27:637–640.
5. Emamifar A, Bjoerndal K, Hansen IM. Is Hearing Impairment Associated with Rheumatoid Arthritis? A Review. *Open Rheumatol J.* 2016 Mar 15;10:26-32.
6. Takatsu M, Higaki M, Kinoshita H, Mizushima Y, Koizuka I. Ear involvement in patients with rheumatoid arthritis. *Otol Neurotol* 2005;26:755–761.
7. Yildirim A, Surucu G, Dogan S, Karabiber M. Relationship between disease activity and hearing impairment in patients with rheumatoid arthritis compared with controls. *Clin Rheumatol.* 2016;35:309-314.
8. Magaro M, Zoli A, Altomonte Z, Mirone L, Corvino G, Di Girolamo S, et al. Sensorineural hearing loss in rheumatoid arthritis. *Clin Exp Rheum* 1990;8:487–490.

- 1
2
3
4 9. Lobo FS, Dossi MO, Batista L, Shinzato MM. Hearing impairment in patients with
5
6 rheumatoid arthritis: association with anti-citrullinated protein antibodies. Clin
7
8
9 Rheumatol. 2016;35:2327-2332
10
- 11
12 10. Salvinelli F, Cancilleri F, Casale M, Luccarelli V, Di Peco V, D'Ascanio L, et al.
13
14
15 Hearing thresholds in patients affected by rheumatoid arthritis. Clin Otolaryngol
16
17
18 2014;29:75–79.
19
- 20
21 11. Pascual-Ramos V, Contreras-Yáñez I, Rivera-Hoyos P, Enríquez L,
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Ramírez-Anguiano J. Cumulative disease activity predicts incidental hearing
impairment in patients with rheumatoid arthritis (RA). Clin Rheumatol 2014;33:
315–321.
12. Bayazit YA, Yilmaz M, Gunduz B, Altinyay S, Kemaloglu YK, Onder M, et al.
Distortion product otoacoustic emission findings in Behçet's disease and
rheumatoid arthritis. ORL J Otorhinolaryngol Relat Spec 2007;69:233–238.
13. Mijovic T, Zeitouni A, Colmegna I. Autoimmune sensorineural hearing loss: the
otology-rheumatology interface. Rheumatology (Oxford) 2013;52:780–789.
14. Ozturk A, Yalcin S, Kaygusuz I, Sahin S, Gok U, Karlidag T, et al. High-frequency
hearing loss and middle ear involvement in rheumatoid arthritis. Am J Otolaryngol
2014;25:411–417.

- 1
2
3
4 15. Cheng SH, Chen CC, Tsai SL. The impacts of DRG-based payments on health care
5
6 provider behaviors under a universal coverage system: a population-based study.
7
8 Health Policy 2012;107:202–208.
9
10
11
12 16. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health
13
14 Insurance Research Database with ischemic stroke cases in Taiwan.
15
16 Pharmacoepidemiol Drug Saf 2011;20:236–242.
17
18
19
20 17. Yu YB, Gau JP, Liu CY, Yang MH, Chiang SC, Hsu HC, et al. A nation-wide
21
22 analysis of venous thromboembolism in 497 180 cancer patients with the
23
24 development and validation of a risk-stratification scoring system. Thromb
25
26 Haemost 2012;108:225–235.
27
28
29
30
31 18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The
32
33 American Rheumatism Association 1987 revised criteria for the classification of
34
35 rheumatoid arthritis. Arthritis Rheum 1988;3:315–324.
36
37
38
39
40 19. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, et al.
41
42 Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for
43
44 confounding. BMJ 2005; 330: 960–962.
45
46
47
48 20. Pascual-Ramos V, Contreras-Yanez I, Enriquez L, Valdes S, Ramirez-Anguiano J
49
50 Hearing impairment in a tertiary-care- level population of Mexican rheumatoid
51
52 arthritis patients. J Clin Rheumatol 2012;18:393–398 .
53
54
55
56
57
58
59
60

- 1
2
3
4 21. Lin C, Lin SW, Weng SF, Lin YS. Risk of sudden sensorineural hearing loss in
5
6 patients with systemic lupus erythematosus: a population-based cohort study.
7
8
9 Audiol Neurootol 2013;18:95–100.
10
11
12 22. Yen YC, Lin YS, Weng SF, Lai FJ. Risk of sudden sensorineural hearing loss in
13
14 patients with psoriasis: a retrospective cohort study. Am J Clin Dermatol
15
16
17 2015;16:213–220.
18
19
20 23. Halligan CS, Bauch CD, Brey RH, Achenbach SJ, Bamlet WR, McDonald TJ, et al.
21
22
23 Hearing loss in rheumatoid arthritis. Laryngoscope 2006;116:2044–2049.
24
25
26 24. Tanaka K, Hamada K, Nakayama T, Matsuda S, Atsumi A, Shimura T, et al. Risk
27
28 for cardiovascular disease in Japanese patients with rheumatoid arthritis: a
29
30 large-scale epidemiological study using a healthcare database. Springerplus. 2016
31
32 19;5:1111. doi: 10.1186/s40064-016-2800-6. eCollection 2016.
33
34
35
36
37 25. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost
38
39
40 2009;7(Suppl 1):328–331.
41
42
43 26. Evans P, Halliwell B. Free radicals and hearing. Cause, consequence, and criteria.
44
45
46 Ann N Y Acad Sci 1999;888:19–40.
47
48
49 27. Semb AG, Kvien TK, Aastveit AH, Jungner I, Pedersen TR, Walldius G, et al.
50
51
52 Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid
53
54
55
56
57
58
59
60

- 1
2
3
4 arthritis in the Apolipoprotein-related Mortality RISK (AMORIS) Study. *Ann*
5
6 *Rheum Dis* 2010;69:1996–2001.
7
8
9 28. Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A. Traditional
10
11 cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. *Joint Bone*
12
13 *Spine* 2011;78:179–183.
14
15
16
17 29. Protogerou, AD, Panagiotakos DB, Zampeli E, Argyris AA, Arida K,
18
19 Konstantonis GD, et al. Arterial hypertension assessed “out of office” in a
20
21 contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease
22
23 is characterized by high prevalence, low awareness, poor control and increased
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- vascular damage-associated “white coat” phenomenon. *Arthritis Res Ther* 2013;15:
R142. doi: 10.1186/ar4324.
30. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al.
Inflammation-associated insulin resistance: differential effects in rheumatoid
arthritis and systemic lupus erythematosus define potential mechanisms. *Arthritis*
Rheum 2008;58:2105–2112.
31. Giles JT, Danielides S, Szklo M, Post WS, Blumenthal RS, Petri M, et al. Insulin
resistance in rheumatoid arthritis: disease-related indicators and associations with
the presence and progression of subclinical atherosclerosis. *Arthritis Rheumatol*
2015;67:626–636.

- 1
2
3
4 32. Dessein PH, Joffe BI, Stanwix AE. Inflammation, insulin resistance, and aberrant
5
6 lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. *J*
7
8
9 *Rheumatol* 2003;30:1403–1405.
10
11
12 33. Kavanaugh A. Dyslipoproteinaemia in a subset of patients with rheumatoid
13
14
15 arthritis. *Ann Rheum Dis* 1994;53:551–552.
16
17
18 34. Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y. Inflammation as a Risk of
19
20
21 Developing Chronic Kidney Disease in Rheumatoid Arthritis. *PLoS One* 2016
22
23 18;11(8). e0160225. doi: 10.1371/journal.pone.0160225. eCollection 2016.
24
25
26 35. Chiu HY, Huang HL, Li CH, Chen HA, Yeh CL, Chiu SH, et.al. Increased Risk of
27
28
29 Chronic Kidney Disease in Rheumatoid Arthritis Associated with Cardiovascular
30
31
32 Complications - A National Population-Based Cohort Study. *PLoS One* 2015;
33
34 10(9):e0136508. doi: 10.1371/journal.pone.0136508. eCollection 2015.
35
36
37 36. Pan XF, Gu JQ, Shan ZY. Increased risk of thyroid autoimmunity in rheumatoid
38
39
40 arthritis: a systematic review and meta-analysis. *Endocrine* 2015;50:79–86.
41
42
43 37. Joshi P, Agarwal A, Vyas S, Kumar R. Prevalence of hypothyroidism in
44
45
46 rheumatoid arthritis and its correlation with disease activity. *Trop Doct*
47
48 2017;47:6-10.
49
50
51 38. Bourji K, Gatto M, Cozzi F, Doria A, Punzi L. Rheumatic and autoimmune thyroid
52
53
54 disorders: a causal or casual relationship? *Autoimmun Rev* 2015;14:57-63.
55
56
57
58
59
60

- 1
2
3
4 39. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid
5
6 arthritis. *Am J Med* 2008;121:S21–31.
7
8
9 40. Susmano A, Rosenbush SW. Hearing loss and ischemic heart disease. *Am J Otol*
10 1988;9:403-408.
11
12 41. Samoriadova OS, Zharova EA, Masenko VP, Balabanova RM, Vil'chinskaia MIu,
13
14 Nasonov EL. The renin-angiotensin-aldosterone system and arterial hypertension in
15
16 patients with rheumatoid arthritis. *Klin Med (Mosk)*. 1991;69:69–71.
17
18
19
20 42. Sakuta T, Morita Y, Satoh M, Fox DA, Kashihara N. Involvement of the
21
22 renin-angiotensin system in the development of vascular damage in a rat model of
23
24 arthritis: effect of angiotensin receptor blockers. *Arthritis Rheum* 2010;62:1319–
25
26 1328.
27
28
29
30
31 43. Dikici O, Muluk NB, Tosun AK, Unlusoy I. Subjective audiological tests and
32
33 transient evoked otoacoustic emissions in patients with rheumatoid arthritis:
34
35 analysis of the factors affecting hearing levels. *Eur Arch Otorhinolaryngol*
36
37 2009;266:1719–1726.
38
39
40
41
42 44. Kastanioudakis I, Skevas A, Danielidis V, Tsiakou E, Drosos AA, Moustopoulos
43
44 MH. Inner ear involvement in rheumatoid arthritis: a prospective clinical study. *The*
45
46 *Journal of laryngology and otology* 1995;109:713–718.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Distribution of demographic factors and comorbidity compared between cohorts

Variable	Non-RA cohort N = 73,068		RA cohort N = 18,267		Standardized mean difference
	n	%	n	%	
Sex					
Female	57288	78.4	14322	78.4	<0.001
Male	15780	21.6	3945	21.6	<0.001
Age, years					
20-39	12224	16.7	3056	16.7	<0.001
40-59	36532	50.0	9133	50.0	<0.001
≥ 60	24312	33.3	6078	33.3	<0.001
Means (SD)	53.3	(14.2)	53.6	(13.9)	0.021
Comorbidity					
DM	8102	11.1	2114	11.6	0.015
Hyperlipidemia	14078	19.3	3439	18.8	0.011
Hypertension	22844	31.3	5964	32.7	0.030
Hyperthyroidism	1089	1.49	456	2.50	0.072
IHD	10993	15.0	2941	16.1	0.029
Stroke	2128	2.91	483	2.64	0.016
CKD	4821	6.60	2061	11.3	0.165
Hypothyroidism	407	0.56	216	1.18	0.067
Autoimmune diseases [†]	433	0.59	534	2.92	0.178

Abbreviation: RA, rheumatoid arthritis; SD, standard deviation; DM, diabetes mellitus; IHD, ischemic heart disease; CKD, chronic kidney disease.

[†]Autoimmune diseases including psoriasis, SLE, systemic sclerosis, Sjogren syndrome, dermatomyositis, polymyositis, and vasculitis.

Table 2. Cox model measured hazard ratios and 95% confidence intervals of hearing loss associated with rheumatoid arthritis and covariates

Variables	Event n	Person-years	Incidence density [#]	HR (95% CI)	
				Univariate	Multivariate [‡]
RA					
No	927	572031	1.62	ref	ref
Yes	429	139085	3.08	1.90 (1.70-2.13)	1.91 (1.70-2.14)
Sex					
Female	977	565205	1.73	ref	ref
Male	379	145912	2.60	1.49 (1.33-1.68)	1.40 (1.24-1.58)
Age, years					
20-39	59	123836	0.48	ref	ref
40-59	563	368175	1.53	3.21 (2.45-4.19)	2.89 (2.21-3.79)
≥ 60	734	219105	3.35	6.98 (5.35-9.10)	5.27 (3.99-6.95)
Comorbidity					
DM					
No	1127	638984	1.76	ref	ref
Yes	229	72133	3.17	1.78 (1.55-2.06)	1.14 (0.98-1.33)
Hyperlipidemia					
No	974	578643	1.68	ref	ref
Yes	382	132474	2.88	1.70 (1.51-1.92)	1.10 (0.97-1.26)
Hypertension					
No	714	499747	1.43	ref	ref
Yes	642	211370	3.04	2.11 (1.90-2.35)	1.21 (1.07-1.38)
Hyperthyroidism					
No	1325	699624	1.89	ref	ref
Yes	31	11492	2.70	1.41 (0.99-2.02)	1.33 (0.92-1.92)
IHD					
No	987	610475	1.62	ref	ref
Yes	369	100642	3.67	2.25 (2.00-2.54)	1.36 (1.19-1.56)
Stroke					
No	1310	695656	1.88	ref	ref
Yes	46	15461	2.98	1.55 (1.15-2.07)	0.85 (0.63-1.14)
CKD					
No	1204	662599	1.82	ref	ref
Yes	152	48517	3.13	1.71 (1.45-2.03)	1.06 (0.89-1.26)
Hypothyroidism					
No	1343	706448	1.90	ref	ref

Yes	13	4668	2.78	1.46 (0.85-2.52)	1.15 (0.65-2.01)
Autoimmune diseases [†]					
No	1334	704142	1.89	ref	ref
Yes	22	6975	3.15	1.65 (1.08-2.51)	1.34 (0.88-2.05)

Abbreviation: HR, hazard ratio; CI, confidence interval; RA, rheumatoid arthritis; DM, diabetes mellitus; IHD, ischemic heart disease; CKD, chronic kidney disease.

[†]Autoimmune diseases including psoriasis, SLE, systemic sclerosis, Sjogren syndrome, dermatomyositis, polymyositis, and vasculitis.

per 1000 person-years

[‡]Multivariate Cox proportional hazards regression model, including RA, sex, age (categorical), DM, hyperlipidemia, hypertension, hyperthyroidism, IHD, stroke, CKD, hypothyroidism, and autoimmune diseases.

Table 3. Incidence density and RA cohort to non-RA cohort hazard ratios of hearing loss by sex, age, and comorbidity in the two cohorts

Variables	Non-RA cohort			RA cohort			RA cohort to non-RA cohort	
	Event no.	Person-years	Incidence density [#]	Event no.	Person-years	Incidence density [#]	Crude	Adjusted [‡]
Sex								
Women	663	454249	1.46	314	110956	2.83	1.94 (1.69-2.22)	1.95 (1.70-2.23)
Men	264	117782	2.24	115	28130	4.09	1.82 (1.46-2.27)	1.85 (1.48-2.30)
Age, years								
20-39	40	98817	0.40	19	25020	0.76	1.89 (1.09-3.26)	1.80 (1.02-3.16)
40-59	355	295193	1.20	208	72982	2.85	2.37 (2.00-2.81)	2.32 (1.95-2.76)
≥ 60	532	178021	2.99	202	41084	4.92	1.63 (1.39-1.92)	1.62 (1.37-1.90)
Comorbidity								
DM								
No	765	514262	1.49	362	124722	2.90	1.95 (1.72-2.21)	1.94 (1.71-2.20)
Yes	162	57770	2.80	67	14363	4.66	1.66 (1.25-2.21)	1.74 (1.30-2.32)
Hyperlipidemia								
No	654	464753	1.41	320	113890	2.81	2.00 (1.75-2.28)	1.96 (1.72-2.25)
Yes	273	107279	2.54	109	25195	4.33	1.69 (1.36-2.11)	1.74 (1.39-2.18)
Hypertension								
No	481	402716	1.19	233	97031	2.40	2.01 (1.72-2.35)	1.94 (1.66-2.28)
Yes	446	169316	2.63	196	42054	4.66	1.76 (1.49-2.08)	1.82 (1.54-2.16)

1									
2									
3									
4									
5									
6									
7	Hyperthyroidism								
8	No	909	563891	1.61	416	135733	3.06	1.90 (1.69-2.13)	1.92 (1.71-2.16)
9	Yes	18	8140	2.21	13	3352	3.88	1.76 (0.86-3.58)	1.72 (0.84-3.55)
10									
11	IHD								
12	No	671	491566	1.37	316	118909	2.66	1.95 (1.70-2.23)	1.96 (1.71-2.24)
13	Yes	256	80466	3.18	113	20176	5.60	1.75 (1.40-2.18)	1.75 (1.40-2.19)
14									
15	Stroke								
16	No	896	559458	1.60	414	136197	3.04	1.90 (1.69-2.13)	1.90 (1.69-2.14)
17	Yes	31	12573	2.47	15	2888	5.19	2.10 (1.13-3.89)	2.18 (1.16-4.12)
18									
19	CKD								
20	No	835	538065	1.55	369	124534	2.96	1.91 (1.69-2.16)	1.94 (1.71-2.19)
21	Yes	92	33967	2.71	60	14551	4.12	1.53 (1.11-2.12)	1.73 (1.25-2.42)
22									
23	Hypothyroidism								
24	No	917	569055	1.61	426	137393	3.10	1.92 (1.71-2.16)	1.94 (1.73-2.18)
25	Yes	10	2977	3.36	3	1692	1.77	0.53 (0.15-1.93)	0.69 (0.19-2.57)
26									
27	Autoimmune diseases [†]								
28	No	916	568956	1.61	418	135186	3.09	1.92 (1.71-2.15)	1.94 (1.73-2.18)
29	Yes	11	3076	3.58	11	3899	2.82	0.79 (0.34-1.82)	0.89 (0.38-2.07)
30									
31									

Abbreviation: RA, rheumatoid arthritis; HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; IHD, ischemic heart disease; CKD, chronic kidney disease.

[†]Autoimmune diseases including psoriasis, SLE, systemic sclerosis, Sjogren syndrome, dermatomyositis, polymyositis, and vasculitis.

[#] per 1000 person-years.

[‡] Model mutually adjusted for sex, age (continuous), DM, hyperlipidemia, hypertension, hyperthyroidism, IHD, stroke, CKD,

1
2
3
4
5
6
7 hypothyroidism, and autoimmune diseases.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table 4. Incidence density and hazard ratios of hearing loss associated with medication in patients with rheumatoid arthritis

Medicine use	N	Event no.	Person-years	Incidence density [#]	HR (95% CI)	
					Crude	Adjusted ^{&}
NSAIDs						
No	169	16	532	30.1	ref	ref
Yes	18098	413	138553	2.98	0.11 (0.07-0.18)	0.12 (0.07-0.20)
Prednisolone						
No	1673	60	11529	5.20	ref	ref
Yes	16594	369	127556	2.89	0.56 (0.43-0.74)	0.53 (0.40-0.70)
DMARDs [†]						
No	2723	90	18643	4.83	ref	ref
Yes	15544	339	120443	2.81	0.59 (0.47-0.74)	0.68 (0.53-0.85)
TNF [‡]						
No	15561	403	116876	3.45	ref	ref
Yes	2706	26	22210	1.17	0.34 (0.23-0.51)	0.40 (0.27-0.59)

Abbreviation: HR, hazard ratio; CI, confidence interval RA, rheumatoid arthritis; NSAID, non-steroidal anti-inflammatory drug; DMARDs, disease-modifying antirheumatic drugs; TNF, tumor necrosis factor.

[†] DMARDs including hydroxychloroquine, sulfasalazine, methotrexate, and leflunomide.

[‡] TNF including etanercept and adalimumab.

[#] per 1000 person-years.

[&] Model adjusted for sex, age, DM, hyperlipidemia, hypertension, hyperthyroidism, IHD, stroke, CKD, hypothyroidism, and autoimmune diseases.


1
2
3
4
5
6
7 Fig 1. Flowchart showing selection of study cohorts
8 LHID, Longitudinal Health Insurance Database; RA, rheumatoid arthritis
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Fig 2. Kaplan-Meier method estimated Cumulative incidence curves of hearing loss in the two cohorts
RA, rheumatoid arthritis

For peer review only



190x107mm (300 x 300 DPI)

Review only



No. at risk

Non-RA cohort	73068	70979	68952	56187	35795	16093
RA cohort	18267	17445	16643	13564	8541	3836

199x209mm (300 x 300 DPI)

STROBE Statement

Checklist of items that should be included in reports of observational studies

Section/Topic	Item No	Recommendation	Reported on Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6,7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7,8
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
Variables	7	(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	7,8
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Data sources/measurement	8*	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Bias	9	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8
Study size	10	Describe any efforts to address potential sources of bias	8
Quantitative variables	11	Explain how the study size was arrived at	7,8
Statistical methods	12	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7,8
		(a) Describe all statistical methods, including those used to control for confounding	8,9
		(b) Describe any methods used to examine subgroups and interactions	8,9
		(c) Explain how missing data were addressed	26
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	26
<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed			
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	9
		(e) Describe any sensitivity analyses	9

Section/Topic	Item No	Recommendation	Reported on Page No
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	26
		(c) Consider use of a flow diagram	26
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10,22
		(b) Indicate number of participants with missing data for each variable of interest	26
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10,27
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10,27
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10,23
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10,11,24
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	13,14
Other Information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Retrospective Cohort Study on Risk of Hearing Loss in Patients with Rheumatoid Arthritis Using Claims Data

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018134.R2
Article Type:	Research
Date Submitted by the Author:	16-Nov-2017
Complete List of Authors:	Huang, Chung-Ming; China Medical University Hospital, Division of Immunology and Rheumatology, Department of Internal Medicine; China Medical University, Graduate Institute of Integrated Medicine, College of Chinese Medicine Chen, Hsuan-Ju; China Medical University Hospital, Management Office for Health Data; China Medical University, College of Medicine Huang, Po-Hao; China Medical University Hospital, Division of Immunology and Rheumatology, Department of Internal Medicine Tsay, Gregory J; China Medical University Hospital, Division of Immunology and Rheumatology, Department of Internal Medicine Lan, Joung-Liang; China Medical University Hospital, Division of Immunology and Rheumatology, Department of Internal Medicine Sung, Fung-Chang; China Medical University Hospital, Management Office for Health Data; China Medical University, Department of Health Services Administration
Primary Subject Heading:	Rheumatology
Secondary Subject Heading:	Epidemiology, Ear, nose and throat/otolaryngology
Keywords:	Rheumatoid arthritis, hearing loss, insurance data,, retrospective cohort study

SCHOLARONE™
Manuscripts

Retrospective Cohort Study on Risk of Hearing Loss in Patients with Rheumatoid Arthritis Using Claims Data

Chung-Ming Huang^{1,2}, Hsuan-Ju Chen^{3,4}, Po-Hao Huang¹, Gregory J Tsay¹,
Joung-Liang Lan¹, Fung-Chang Sung^{3,5}

Running Title: Hearing loss in rheumatoid arthritis

¹Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan;

²Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan

³Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan

⁴College of Medicine, China Medical University, Taichung, Taiwan

⁵Department of Health Services Administration, China Medical University, Taichung, Taiwan

Corresponding author:

Fung-Chang Sung, PhD, MPH
Department of Health Services Administration, China Medical University
91 Hsueh Shih Road
Taichung 404, Taiwan
Tel: 886-4-2205-4070
Fax: 886-4-2235-8326
E-mail: fcsung1008@yahoo.com

Word count: Abstract 238; Strength and limitation 150; Text 2658; 5 Tables; 2 Figures.

ABSTRACT

Objectives Population studies on hearing loss (HL) associated with rheumatoid arthritis (RA) are lacking. This study investigated the risk of developing HL in patients with RA using a nationwide population cohort.

Setting The population-based insurance claims data in the Taiwan National Health Insurance Research Database

Design Retrospective cohort study followed up RA cohort and control cohort without RA frequency-matched by sex, age, and diagnosis year.

Study population 18,267 RA patients newly diagnosed in 2000-2006 and 73,068 controls without RA.

Main outcomes Incidences of HL by the end of 2011 and the RA cohort to non-RA cohort hazard ratios (HRs) after adjusting for sex, age, and comorbidities.

Results The HL incidence was higher in the RA cohort than in the non-RA cohort (3.08 versus 1.62 per 1000 person-years), with an adjusted HR of 1.91 (95% confidence interval = 1.70-2.14) for the RA cohort relative to the non-RA cohort after controlling for age, sex, and comorbidities. Men and the elderly are at a higher risk. Cardiovascular comorbidities were associated with a further increased HL risk for RA

1
2
3 patients. Medications were associated with reduced HL incidence; RA patients who
4
5
6 used NSAIDs had an aHR of 0.12 (95% CI = 0.07-0.20), compared with non-users.
7
8
9

10 **Conclusions** This study demonstrates that patients with RA are at an increased risk of
11
12 developing HL. Findings highlight the need of disease-modifying treatment and
13
14 scheduled auditory examinations for HL prevention and early detection for RA
15
16 patients.
17
18
19
20
21

22 **Keywords:** Rheumatoid arthritis, hearing loss, insurance data, retrospective cohort
23
24 study
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

1. The strength of this study is the use of a nationwide population-based cohort to identify HL risk in an Asian population with RA. Our findings can be generalized to the general population.
2. The inclusion of the Catastrophic Illness Patient Database confirmed the diagnoses of all RA cases with increased the reliability of our data; the large sample size reduced the tendency for selection bias, enhanced statistical power and precision of risk appraisal.
3. Limitations in this study: Information on several suspected risk factors for HL, such as smoking and chronic exposure to occupational and environmental noise, which could be associated with HL in the general population, were not available in the insurance database.
4. Information on laboratory test results and HL by severity and sound frequency (high, mid or low frequency), and on RA severity scale, such as disease activity, functional impairment and physical damage was also unavailable.

INTRODUCTION

Rheumatoid arthritis (RA) is a disease predominantly characterized by chronic joint inflammation and is often accompanied by several peripheral inflammatory manifestations.¹ RA may lead to the destruction of the cartilage and bone due to chronic synovitis and may consequently impair joint function.² In addition, patients with RA may have extra-articular manifestations involving other organ systems,³ such as auditory system alteration, although with a different putative mechanism of damage.⁴⁻⁶ With respect to the auditory system, previous studies have shown conflicting findings, in both hearing loss (HL) and the RA disease activity and severity.⁷⁻¹⁰

There are a wide variations in the reported prevalence of HL in patients with RA. Sensorineural hearing loss (SNHL) is the most common hearing impairment in patients with RA, ranging from 25 to 72%,¹¹ whereas conductive HL and mixed HL are less frequently reported.^{4,6,12} SNHL could be induced by a direct immune response of either T or B cells against inner ear proteins.¹³ Neurovascular inflammation and drugs used for RA treatment could also damage the cochlea.¹⁴ Thus, HL may be a manifestation of systemic vascular involvement in patients with RA and may have a significant effect on the health of patients with RA. However, the risk of developing HL in patients with RA has not been well examined using population data.

1
2
3
4 Hence, the purpose of this study was to investigate the risk of HL in patients with
5
6 RA, using representative insurance claims data obtained from the Taiwan National
7
8 Health Insurance (NHI). The HL risk associated with other comorbidities, such as
9
10 coronary heart disease, hypertension, stroke, diabetes, hyperlipidemia,
11
12 hyperthyroidism, hypothyroidism, chronic renal disease and autoimmune diseases,
13
14 were also evaluated.
15
16
17
18
19
20
21
22

23 **MATERIALS AND METHODS**

24 **Data source**

25
26
27
28
29 The Taiwan NHI system is a single-payer compulsory programme with a
30
31 coverage of over 99% of 23.74 million people.¹⁵ We conducted this study using two
32
33 data sets: the Registry for Catastrophic Illness Patient Database (CIPD) and the
34
35 Longitudinal Health Insurance Database (LHID2000), obtained from the Taiwan
36
37 National Health Research Institutes. Patients with major diseases, such as cancer,
38
39 chronic mental illness, end-stage renal disease and several autoimmune diseases
40
41 requiring long-term care are eligible for the CIPD coverage for exemption from
42
43 making co-payment. The LHID2000 contains the claims data of 1,000,000 people
44
45 randomly sampled from all populations being registered in 2000 for the insurance
46
47 coverage. Reimbursement claims data for medical services from 1996 to 2011 in both
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 data sets were used in this study. For privacy protection, all personal identifications
5
6 were replaced with surrogate identifications suitable for public use and data linkage.
7

8
9 The claims data contained information on the demographic status of the insured
10
11 people, dates of treatment and treatments received, diagnostic codes, prescriptions,
12
13 and costs. Diagnoses of diseases were coded with the International Classification of
14
15 Disease Diagnoses, 9th Revision of Clinical Modification (ICD-9-CM). Several
16
17 studies in Taiwan using the insurance claims data have demonstrated high accuracy
18
19 and validity of ICD-9 diagnosis.^{16,17} This study was approved by the Research Ethics
20
21 Committee of China Medical University and Hospital (CMUH104-REC2-115).
22
23
24
25
26
27
28

29 **Study population**

30
31
32 Figure 1 shows the flowchart for identifying and selecting study population using
33
34 a population-based retrospective cohort study design. We identified a RA cohort from
35
36 the registry for CIPD and a non-RA cohort from the LHID2000. Patients newly
37
38 diagnosed with RA (ICD-9-CM 714.0) from 2000 to 2006 without HL were included
39
40 in the RA cohort. The date with RA certificated as the catastrophic illness was
41
42 considered as the index date for the approved patients. Patients who met four or more
43
44 of the diagnostic criteria based on the 1987 American College of Rheumatology
45
46 criteria were considered as having RA and those diagnosed by rheumatologists were
47
48 included in the RA cohort.¹⁸ The application for catastrophic illness status was
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 scrutinized by peer review.
5

6 For each patient with RA, four insured people without history of RA and HL
7
8 were randomly selected from the LHID2000 for the non-RA cohort and were
9
10 frequency-matched by sex, age (each 5-year span), and index year. Individuals with
11
12 missing information on age and/or sex or with history of HL (ICD-9-CM 388.2, 388.4,
13
14 389.00, 389.10, 389.12, 389.2, and 389.9) at baseline were excluded from the non-RA
15
16 cohort.
17
18
19
20
21

22
23 Both cohorts were followed from the index date to the date with HL diagnosed,
24
25 death, withdrawal from the NHI system, or the end of 2011. In general, HL was
26
27 diagnosed based on the audiometry test. To increase the validity of HL diagnosis, only
28
29 patients with three or more diagnoses in outpatient claims or an inpatient record were
30
31 included in the study. Patients who were suspected of having HL received
32
33 comprehensive examinations and, subsequently, treatment was followed when the
34
35 disorder was confirmed. In the insurance system, HL patients' medical reimbursement
36
37 and discharge notes are scrutinised by peer review. The insurance system also
38
39 randomly reviewed insurance claims to prevent errors and violations. Therefore,
40
41 diagnoses and codes of HL in the study were highly reliable.¹⁶
42
43
44
45
46
47
48
49

50 51 **Statistical analysis** 52

53
54 Distributions of sex and age (20-39, 40-59, and ≥ 60 years) and baseline
55
56
57
58
59

1
2
3
4 comorbidities, including diabetes (ICD-9-CM 250), hyperlipidemia (ICD-9-CM 272),
5
6
7 hypertension (ICD-9-CM 401-405), hyperthyroidism (ICD-9-CM 242), ischemic heart
8
9
10 disease (IHD; ICD-9-CM 410-414), stroke (ICD-9-CM 430-438), chronic kidney
11
12
13 disease (CKD; ICD-9-CM 580-589), hypothyroidism (ICD-9-CM 244), and
14
15
16 autoimmune diseases (including psoriasis [ICD-9-CM 696], systemic lupus
17
18
19 erythematosus [ICD-9-CM 710.0], systemic sclerosis [ICD-9-CM 710.1], Sjogren
20
21
22 syndrome [ICD-9-CM 710.2], dermatomyositis [ICD-9-CM 710.3], polymyositis
23
24
25 [ICD-9-CM 710.4], and vasculitis [ICD-9-CM 446.0, 446.2, 446.4, 446.5, 443.1,
26
27
28 446.7, 446.1, and 136.1]), between the RA and non-RA cohorts were compared. A
29
30
31 standardized mean difference of less than 0.1 was a negligible difference between two
32
33
34 means or two prevalence rates¹⁹. The incidence density of HL per 1000 person-years
35
36
37 was calculated during the follow-up period by sex, age and comorbidity. The
38
39
40 Kaplan-Meier method was employed to plot the cumulative incidence of HL for each
41
42
43 cohort during the follow-up period, and the log-rank test was used to assess the
44
45
46 differences between the two curves. Univariate and multivariate Cox proportional
47
48
49 hazards regression analyses were used to measure the RA cohort to non-RA cohort
50
51
52 crude hazard ratio (cHR) and adjusted hazard ratio (aHR) of HL, respectively, and
53
54
55 their 95% confidence intervals (CIs). Sex, age, and comorbidities including diabetes,
56
57
58 hyperlipidemia, hypertension, hyperthyroidism, hypothyroidism, IHD, stroke, CKD
59
60

1
2
3
4 and autoimmune diseases, were included as covariates in the multivariate Cox
5
6 regression analysis. To further assess the robustness of our results, we also evaluated
7
8 the association between RA and HL risk in various subgroups by sex, age, and each
9
10 comorbidity. We further evaluated the treatment effectiveness of medications for RA
11
12 patients by calculating the incidence density and HRs of HL. The HL relating to
13
14 medications for RA treatment was evaluated, including nonsteroidal
15
16 anti-inflammatory drugs (NSAIDs), prednisolone, disease-modifying antirheumatic
17
18 drugs (DMARDs, including hydroxychloroquine, sulfasalazine, methotrexate, and
19
20 leflunomide), and tumor necrosis factor (TNF, including etanercept and adalimumab).
21
22 Further analysis evaluated the HL risk by the type of HL: sensorineural, conductive or
23
24 mixed.
25
26
27
28
29
30
31
32
33

34 All analyses were conducted using SAS statistical software (version 9.4 for
35
36 Windows; SAS Institute, Cary, North Carolina, USA), and all statistical tests were
37
38 performed at the two-tailed significance level of 0.05.
39
40
41
42
43
44
45

46 **RESULTS**

47
48 We identified 18,267 RA patients newly diagnosed from 2000 to 2006 for the
49
50 RA cohort and 73,068 persons without RA for the non-RA cohort as controls (Table
51
52 1). There were more women than men (78.4 vs. 21.6%) in both cohorts.
53
54
55
56
57
58
59
60

1
2
3
4 Approximately 66.7% of the study populations were <60 years old. Prevalence rates
5
6 of CKD and autoimmune diseases were more prevalent in patients with RA than in
7
8 controls at the baseline.
9

10
11 The Kaplan-Meier method estimated cumulative incidence of HL was 1.5%
12
13 greater in the RA cohort than in the non-RA cohort (3.3 vs. 1.8%; p value < 0.001 in
14
15 the log-rank test) (Fig. 2). The incidence density of HL was approximately two-fold
16
17 greater in the RA cohort than in the non-RA cohort (3.08 vs. 1.62 per 1000
18
19 person-years), with an aHR of 1.91 (95% CI = 1.70-2.14) (Table 2). Men were at a
20
21 greater risk of HL than women, and the risk increased with age. Compared to 20–39
22
23 years old, the aHRs of HL were 2.89 (95% CI = 2.21-3.79) and 5.27 (95% CI =
24
25 3.99-6.95) for those aged 40-59 and those aged ≥ 60 years, respectively. The HL risk
26
27 for individuals with comorbidities was also elevated. Patients with hypertension and
28
29 IHD were significantly associated with higher risk of HL compared with their
30
31 counterparts without the disorder, with aHRs of 1.21 (95% CI = 1.07-1.38) and of
32
33 1.36 (95% CI = 1.19-1.56), respectively.
34
35
36
37
38
39
40
41
42
43
44
45

46 Table 3 shows that incidence rates of HL stratified by sex, age, and comorbidity
47
48 were consistently greater in the RA cohort than in the non-RA cohort. Comorbidity
49
50 was associated with further increased HL risk for RA patients. RA patients with
51
52 comorbid IHD had the highest incident HL, 5.60 per 1000 person-years.
53
54
55
56
57
58
59
60

1
2
3
4 Table 4 shows that medications were associated with reduced incident HL for RA
5
6 patients. Near 99% of RA patients used NSAIDs and users had a HL incidence of 2.98
7
8 per 1000 person-years, with an aHR of 0.12 (95% CI = 0.07-0.20) compared with
9
10 non-users who had an incidence of 30.1 per 1000 person-years for HL. RA patients on
11
12 medications of adalimumab (n = 950) had the lowest HL incidence of 0.64 per 1000
13
14 person-years with an aHR of 0.23 (95% CI = 0.10-0.55), compared with non-users
15
16 who had an incidence of 3.23 per 1000 person-years.
17
18
19
20
21
22

23 Further evaluation on the subtype HL showed that RA patients had only few cases
24
25 of conductive HL, but were at increased risk of sensorineural HL and mixed HL with
26
27 adjusted HRs of 2.35 (95% CI = 1.91–2.89) and 1.77 (95% CI = 1.54–2.03),
28
29 respectively (Table 5).
30
31
32
33

34 **DISCUSSION**

35
36
37 This retrospective cohort study showed that patients with RA were nearly two-fold
38
39 more likely to develop HL than those without RA. The risk of HL associated with RA
40
41 increased with age. In the RA cohort, those ≥ 60 years old had an HL incidence of 4.92
42
43 per 1000 person-years, which was 4.16 per 1000 person-year greater than that of
44
45 patients aged 20-39 years. The corresponding difference was 2.49 per 1000
46
47 person-years between the 2 age groups in the non-RA cohort, reflecting the natural HL
48
49 by aging in the non-RA cohort. Similar to reports in other studies, HL is age dependent
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 in patients and control subjects.^{6,14,20} This finding is also consistent with previous
5
6 studies for patients with sudden sensorineural hearing loss comorbid with systemic
7
8 lupus erythematosus and psoriasis,^{21,22} The excess HL risk could be 50% in patients
9
10 with psoriasis.
11
12
13

14
15 We also found that, in the RA cohort, men had an incidence of 4.09 per 1000
16
17 person-years for HL, which was 1.26 per 1000 person-years greater than women had.
18
19 The corresponding difference was 0.78 per 1000 person-years in the non-RA cohort,
20
21 indicating the relationship between RA and HL risk may be slightly greater for men. In
22
23 the entire study population, the overall aHR was 1.40 for men compared with women
24
25 (Table 2). There is a remarkable imbalance between the number of males and females
26
27 with autoimmune diseases, with females representing the majority of cases. Although
28
29 reasons for this overrepresentation of women are unclear, genetic (X-linked) factors and
30
31 hormonal aspects are likely involved. Halligan et al.²³ investigated patients with RA
32
33 and also demonstrated that the prevalence of abnormal hearing is significantly greater
34
35 in males (86% or 12/14) than in females (33% or 5/15) ($p = 0.008$). However, no
36
37 significant gender difference in HL among those without RA was found ($p = 0.715$).
38
39
40
41
42
43
44
45
46
47
48

49 Evidences have shown that patients with RA are prevalent with comorbidities, such
50
51 as IHD²⁴⁻²⁶, stroke²⁷, hypertension^{28,29}, diabetes³⁰⁻³², dyslipidemia^{27,33}, CKD^{34,35} and
52
53 thyroid disorders³⁶⁻³⁸. In this study, the study populations in both cohorts were young.
54
55
56
57
58
59
60

1
2
3
4 The baseline prevalence rates of most comorbidities between the 2 cohorts were not
5
6 significantly different, except that CKD and autoimmune diseases were more prevalent
7
8 in patients with RA than in controls without RA at the baseline (Table 1). However, it is
9
10 interest to note that most of the comorbidities are associated with further increased
11
12 incidence of HL, greater for the RA cohort than for the non-RA cohort, except
13
14 hypothyroidism, and autoimmune diseases (Table 3). Autoimmune disease is a possible
15
16 pathology associated with sensorineural hearing loss because of the destruction of the
17
18 cochlear hair cells.³⁹ Our study failed to prove this relationship.
19
20
21
22
23
24
25

26 The development of RA and the breakdown of atherosclerotic plaques possibly
27
28 share common factors contributing to inflammatory cells and pro-inflammatory
29
30 cytokines.²⁵ Pro-inflammatory cytokines may contribute to the oxidative damage in the
31
32 inner ear.²⁶ For example, both tumor necrosis factor (TNF)- α and interleukin (IL)-6 are
33
34 involved in the pathogenesis of both RA and atherosclerosis.⁴⁰ However, Takatsu et al.
35
36 showed that the pro-inflammatory cytokines (IL-6) and matrix metalloproteinase (MMP)
37
38 -3 may contribute to harm inner ear cells by an oxidative process.⁶ Both RA and HL
39
40 may have a shared mechanism associating with cardiovascular diseases which account
41
42 for the higher risk of hearing loss in patients with RA. IHD alone may associate with
43
44 HL. An earlier study found patients with IHD are prevalent with HL for up to over
45
46 30%.⁴¹ Moreover, in this study, we found that patients with RA with IHD had the
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 highest HL incidence among patients with cardiovascular disorders. Hence, RA and
5
6 cardiovascular disorders may have a shared contribution to the HL risk.
7

8
9 Furthermore, several studies have reported elevated plasma renin and
10
11 angiotensin-converting enzyme (ACE) activities in patients with RA.^{42,43} Poor blood
12
13 pressure control could induce changes in the renin-angiotensin system. Higher
14
15 oxidative stress in patients with RA could also impair the vasodilatory mechanism of
16
17 the endothelium,⁴³ which could be associated with the higher HL risk in patients with
18
19 RA. Hence, hypertension is likely another risk factor contributing to HL. The findings
20
21 in our study further demonstrate the association between autoimmune disease and HL
22
23 risk.
24
25
26
27
28
29
30

31
32 After adjustment for sex, age, and comorbidity, we found reduced HL risk for
33
34 RA patients on medication of NSAID, prednisolone, DMARDs and TNF. Conversely,
35
36 Halligan et al.²³ described an association between HL and hydroxychloroquine, and
37
38 Dikici et al.⁴⁴ observed a dose relation between HL using methotrexate. On the other
39
40 hand, some studies found no relationship between HL and RA treatment using NSAID,
41
42 corticosteroid and DMARDs.^{6,9,20,45} The inconsistent results may be due to the
43
44 relatively small study sample sizes, while our study is a nationwide population-based
45
46 cohort with large sample size. It is likely, the reduced inflammation in patients with RA
47
48 on medications of NSAID, corticosteroid, DMARDs and TNF could be associated with
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 reducing the HL risk.
5

6 The strength of this study is the use of a nationwide population-based cohort to
7 evaluate HL risk in an Asian population with RA. Our findings can be generalized to
8 the general population. The large sample size allowed the identification of risk factors
9 associated with the development of HL in Taiwan with a minimal tendency for
10 selection bias, and enhanced the statistical power and precision of risk appraisal. In
11 addition, the inclusion of the CIPD confirmed the diagnoses of all RA cases in the
12 NHIRD database, which increased the reliability of our data.
13
14
15
16
17
18
19
20
21
22
23
24

25 However, several limitations to the interpretation of our findings should be
26 considered. Information on several suspected risk factors for HL was unavailable, such
27 as smoking and chronic exposure to occupational and environmental noise, which could
28 be associated with HL for both cohorts. Moreover, information was also unavailable on
29 laboratory test results, HL severity and RA severity scale and activity, functional
30 impairment and physical damage of the disease. Hearing impairments by specific sound
31 frequency were not measured to differentiate high, mid or low frequency HL.
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 In conclusion, this study demonstrated that patients with RA are at an elevated
47 risk of developing HL. Our findings also suggest the need for prompt treatment and
48 early detection of RA for HL prevention. Appropriate and timely medical interventions
49 may improve the prognosis of HL for patients diagnosed with RA.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 **Contributors** The paper was conceived by CMH, HJC, PHH, GJT and JLL. CMH,
8
9 HJC and FCS wrote the first draft, with further contributions from all authors.
10
11
12 Statistical analyses were undertaken by CMH, HJC and FCS. CMH and FCS revised
13
14
15 the article. All authors contributed to data interpretation, reviewed and approved the
16
17
18 final version of the manuscript.
19

20 **Funding** This study was supported by the Taiwan Ministry of Health and Welfare
21
22
23 Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004);
24
25
26 China Medical University Hospital; Academia Sinica Taiwan Biobank, Stroke
27
28
29 Biosignature Project (BM10601010036); Taiwan Clinical Trial Consortium for Stroke
30
31
32 (MOST 106-2321-B-039-005); Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan
33
34
35 Brain Disease Foundation, Taipei, Taiwan; and Katsuzo and Kiyo Aoshima Memorial
36
37
38 Funds, Japan, for their support.
39

40 **Conflict of interest:** None.
41

42
43 **Competing interests:** None declared.
44

45
46 **Provenance and peer review:** Not commissioned; externally peer reviewed.
47

48
49 **Data sharing statement:** No additional data are available.
50
51
52
53
54
55
56
57
58
59

REFERENCES:

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. *Lancet* 2010;376:1094–1098.
2. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. *N Engl J Med* 1990;322:1277-1289.
3. Ozcan M, Karakus MF, Gunduz OH, Tuncel U, Sahin H. Hearing loss and middle ear involvement in rheumatoid arthritis. *Rheumatol Int* 2002;22:16–19.
4. Murdin L, Patel S, Walmsley J, Yeoh LH. Hearing difficulties are common in patients with rheumatoid arthritis. *Clin Rheumatol* 2008;27:637–640.
5. Emamifar A, Bjoerndal K, Hansen IM. Is Hearing Impairment Associated with Rheumatoid Arthritis? A Review. *Open Rheumatol J.* 2016 Mar 15;10:26-32.
6. Takatsu M, Higaki M, Kinoshita H, Mizushima Y, Koizuka I. Ear involvement in patients with rheumatoid arthritis. *Otol Neurotol* 2005;26:755–761.
7. Yildirim A, Surucu G, Dogan S, Karabiber M. Relationship between disease activity and hearing impairment in patients with rheumatoid arthritis compared with controls. *Clin Rheumatol.* 2016;35:309-314.
8. Magaro M, Zoli A, Altomonte Z, Mirone L, Corvino G, Di Girolamo S, et al. Sensorineural hearing loss in rheumatoid arthritis. *Clin Exp Rheum* 1990;8:487–490.

- 1
2
3
4 9. Lobo FS, Dossi MO, Batista L, Shinzato MM. Hearing impairment in patients with
5
6 rheumatoid arthritis: association with anti-citrullinated protein antibodies. Clin
7
8
9 Rheumatol. 2016;35:2327-2332
10
- 11
12 10. Salvinelli F, Cancilleri F, Casale M, Luccarelli V, Di Peco V, D'Ascanio L, et al.
13
14
15 Hearing thresholds in patients affected by rheumatoid arthritis. Clin Otolaryngol
16
17
18 2014;29:75–79.
19
- 20
21 11. Pascual-Ramos V, Contreras-Yáñez I, Rivera-Hoyos P, Enríquez L,
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Ramírez-Anguiano J. Cumulative disease activity predicts incidental hearing
impairment in patients with rheumatoid arthritis (RA). Clin Rheumatol 2014;33:
315–321.
12. Bayazit YA, Yilmaz M, Gunduz B, Altinyay S, Kemaloglu YK, Onder M, et al.
Distortion product otoacoustic emission findings in Behçet's disease and
rheumatoid arthritis. ORL J Otorhinolaryngol Relat Spec 2007;69:233–238.
13. Mijovic T, Zeitouni A, Colmegna I. Autoimmune sensorineural hearing loss: the
otology-rheumatology interface. Rheumatology (Oxford) 2013;52:780–789.
14. Ozturk A, Yalcin S, Kaygusuz I, Sahin S, Gok U, Karlidag T, et al. High-frequency
hearing loss and middle ear involvement in rheumatoid arthritis. Am J Otolaryngol
2014;25:411–417.

- 1
2
3
4 15. Cheng SH, Chen CC, Tsai SL. The impacts of DRG-based payments on health care
5
6 provider behaviors under a universal coverage system: a population-based study.
7
8 Health Policy 2012;107:202–208.
9
10
11
12 16. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health
13
14 Insurance Research Database with ischemic stroke cases in Taiwan.
15
16 Pharmacoepidemiol Drug Saf 2011;20:236–242.
17
18
19
20 17. Yu YB, Gau JP, Liu CY, Yang MH, Chiang SC, Hsu HC, et al. A nation-wide
21
22 analysis of venous thromboembolism in 497 180 cancer patients with the
23
24 development and validation of a risk-stratification scoring system. Thromb
25
26 Haemost 2012;108:225–235.
27
28
29
30
31 18. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The
32
33 American Rheumatism Association 1987 revised criteria for the classification of
34
35 rheumatoid arthritis. Arthritis Rheum 1988;3:315–324.
36
37
38
39
40 19. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, et al.
41
42 Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for
43
44 confounding. BMJ 2005; 330: 960–962.
45
46
47
48
49 20. Pascual-Ramos V, Contreras-Yanez I, Enriquez L, Valdes S, Ramirez-Anguiano J
50
51 Hearing impairment in a tertiary-care- level population of Mexican rheumatoid
52
53 arthritis patients. J Clin Rheumatol 2012;18:393–398 .
54
55
56
57
58
59
60

- 1
2
3
4 21. Lin C, Lin SW, Weng SF, Lin YS. Risk of sudden sensorineural hearing loss in
5
6 patients with systemic lupus erythematosus: a population-based cohort study.
7
8
9 Audiol Neurotol 2013;18:95–100.
10
11
12 22. Yen YC, Lin YS, Weng SF, Lai FJ. Risk of sudden sensorineural hearing loss in
13
14 patients with psoriasis: a retrospective cohort study. Am J Clin Dermatol
15
16
17 2015;16:213–220.
18
19
20 23. Halligan CS, Bauch CD, Brey RH, Achenbach SJ, Bamlet WR, McDonald TJ, et al.
21
22
23 Hearing loss in rheumatoid arthritis. Laryngoscope 2006;116:2044–2049.
24
25
26 24. Tanaka K, Hamada K, Nakayama T, Matsuda S, Atsumi A, Shimura T, et al. Risk
27
28 for cardiovascular disease in Japanese patients with rheumatoid arthritis: a
29
30 large-scale epidemiological study using a healthcare database. Springerplus. 2016
31
32
33 19;5:1111. doi: 10.1186/s40064-016-2800-6. eCollection 2016.
34
35
36
37 25. Hansson GK. Inflammatory mechanisms in atherosclerosis. J Thromb Haemost
38
39
40 2009;7(Suppl 1):328–331.
41
42
43 26. Evans P, Halliwell B. Free radicals and hearing. Cause, consequence, and criteria.
44
45
46 Ann N Y Acad Sci 1999;888:19–40.
47
48
49 27. Semb AG, Kvien TK, Aastveit AH, Jungner I, Pedersen TR, Walldius G, et al.
50
51
52 Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid
53
54
55
56
57
58
59
60

- 1
2
3
4 arthritis in the Apolipoprotein-related Mortality RISK (AMORIS) Study. *Ann*
5
6 *Rheum Dis* 2010;69:1996–2001.
7
8
9 28. Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A. Traditional
10
11 cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. *Joint Bone*
12
13 *Spine* 2011;78:179–183.
14
15
16
17 29. Protogerou, AD, Panagiotakos DB, Zampeli E, Argyris AA, Arida K,
18
19 Konstantonis GD, et al. Arterial hypertension assessed “out of office” in a
20
21 contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease
22
23 is characterized by high prevalence, low awareness, poor control and increased
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- vascular damage-associated “white coat” phenomenon. *Arthritis Res Ther* 2013;15:
R142. doi: 10.1186/ar4324.
30. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al.
Inflammation-associated insulin resistance: differential effects in rheumatoid
arthritis and systemic lupus erythematosus define potential mechanisms. *Arthritis*
Rheum 2008;58:2105–2112.
31. Giles JT, Danielides S, Szklo M, Post WS, Blumenthal RS, Petri M, et al. Insulin
resistance in rheumatoid arthritis: disease-related indicators and associations with
the presence and progression of subclinical atherosclerosis. *Arthritis Rheumatol*
2015;67:626–636.

- 1
2
3
4 32. Dessein PH, Joffe BI, Stanwix AE. Inflammation, insulin resistance, and aberrant
5
6 lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. *J*
7
8
9 *Rheumatol* 2003;30:1403–1405.
10
11
12 33. Kavanaugh A. Dyslipoproteinaemia in a subset of patients with rheumatoid
13
14
15 arthritis. *Ann Rheum Dis* 1994;53:551–552.
16
17
18 34. Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y. Inflammation as a Risk of
19
20
21 Developing Chronic Kidney Disease in Rheumatoid Arthritis. *PLoS One* 2016
22
23 18;11(8). e0160225. doi: 10.1371/journal.pone.0160225. eCollection 2016.
24
25
26 35. Chiu HY, Huang HL, Li CH, Chen HA, Yeh CL, Chiu SH, et.al. Increased Risk of
27
28
29 Chronic Kidney Disease in Rheumatoid Arthritis Associated with Cardiovascular
30
31
32 Complications - A National Population-Based Cohort Study. *PLoS One* 2015;
33
34 10(9):e0136508. doi: 10.1371/journal.pone.0136508. eCollection 2015.
35
36
37 36. Pan XF, Gu JQ, Shan ZY. Increased risk of thyroid autoimmunity in rheumatoid
38
39
40 arthritis: a systematic review and meta-analysis. *Endocrine* 2015;50:79–86.
41
42
43 37. Joshi P, Agarwal A, Vyas S, Kumar R. Prevalence of hypothyroidism in
44
45
46 rheumatoid arthritis and its correlation with disease activity. *Trop Doct*
47
48 2017;47:6-10.
49
50
51 38. Bourji K, Gatto M, Cozzi F, Doria A, Punzi L. Rheumatic and autoimmune thyroid
52
53
54 disorders: a causal or casual relationship? *Autoimmun Rev* 2015;14:57-63.
55
56
57
58
59
60

- 1
2
3
4 39. Goodall AF, Siddiq MA. Current understanding of the pathogenesis of
5
6 autoimmune inner ear disease: a review. *Clin Otolaryngol* 2015;40: 412–419.
7
8
9 40. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid
10
11 arthritis. *Am J Med* 2008;121:S21–31. adequate
12
13
14 41. Susmano A, Rosenbush SW. Hearing loss and ischemic heart disease. *Am J Otol*
15
16 1988;9:403-408.
17
18 42. Samoriadova OS, Zharova EA, Masenko VP, Balabanova RM, Vil'chinskaia MIu,
19
20 Nasonov EL. The renin-angiotensin-aldosterone system and arterial hypertension in
21
22 patients with rheumatoid arthritis. *Klin Med (Mosk)*. 1991;69:69–71.
23
24
25
26 43. Sakuta T, Morita Y, Satoh M, Fox DA, Kashihara N. Involvement of the
27
28 renin-angiotensin system in the development of vascular damage in a rat model of
29
30 arthritis: effect of angiotensin receptor blockers. *Arthritis Rheum* 2010;62:1319–
31
32 1328.
33
34
35
36
37 44. Dikici O, Muluk NB, Tosun AK, Unlusoy I. Subjective audiological tests and
38
39 transient evoked otoacoustic emissions in patients with rheumatoid arthritis:
40
41 analysis of the factors affecting hearing levels. *Eur Arch Otorhinolaryngol*
42
43 2009;266:1719–1726.
44
45
46
47
48 45. Kastanioudakis I, Skevas A, Danielidis V, Tsiakou E, Drosos AA, Moustopoulos
49
50 MH. Inner ear involvement in rheumatoid arthritis: a prospective clinical study. *J*
51
52 *Laryngol Otol* 1995;109:713–718.
53
54
55
56
57
58
59
60

Table 1. Distribution of demographic factors and comorbidity compared between cohorts

Variable	Non-RA cohort N = 73,068		RA cohort N = 18,267		Standardized mean difference
	n	%	n	%	
Sex					
Female	57288	78.4	14322	78.4	<0.001
Male	15780	21.6	3945	21.6	<0.001
Age, years					
20-39	12224	16.7	3056	16.7	<0.001
40-59	36532	50.0	9133	50.0	<0.001
≥ 60	24312	33.3	6078	33.3	<0.001
Means (SD)	53.3	(14.2)	53.6	(13.9)	0.021
Comorbidity					
DM	8102	11.1	2114	11.6	0.015
Hyperlipidemia	14078	19.3	3439	18.8	0.011
Hypertension	22844	31.3	5964	32.7	0.030
Hyperthyroidism	1089	1.49	456	2.50	0.072
IHD	10993	15.0	2941	16.1	0.029
Stroke	2128	2.91	483	2.64	0.016
CKD	4821	6.60	2061	11.3	0.165
Hypothyroidism	407	0.56	216	1.18	0.067
Autoimmune diseases [†]	433	0.59	534	2.92	0.178

Abbreviation: RA, rheumatoid arthritis; SD, standard deviation; DM, diabetes mellitus; IHD, ischemic heart disease; CKD, chronic kidney disease.

[†]Autoimmune diseases including psoriasis, SLE, systemic sclerosis, Sjogren syndrome, dermatomyositis, polymyositis, and vasculitis.

Table 2. Cox model measured hazard ratios and 95% confidence intervals of hearing loss associated with rheumatoid arthritis and covariates

Variables	Event n	Person-years	Incidence density #	HR (95% CI)	
				Univariate	Multivariate [‡]
RA					
No	927	572031	1.62	ref	ref
Yes	429	139085	3.08	1.90 (1.70-2.13)***	1.91 (1.70-2.14)***
Sex					
Female	977	565205	1.73	ref	ref
Male	379	145912	2.60	1.49 (1.33-1.68)***	1.40 (1.24-1.58)***
Age, years					
20-39	59	123836	0.48	ref	ref
40-59	563	368175	1.53	3.21 (2.45-4.19)***	2.89 (2.21-3.79)***
≥ 60	734	219105	3.35	6.98 (5.35-9.10)***	5.27 (3.99-6.95)***
Comorbidity					
DM					
No	1127	638984	1.76	ref	ref
Yes	229	72133	3.17	1.78 (1.55-2.06)***	1.14 (0.98-1.33)
Hyperlipidemia					
No	974	578643	1.68	ref	ref
Yes	382	132474	2.88	1.70 (1.51-1.92)***	1.10 (0.97-1.26)
Hypertension					
No	714	499747	1.43	ref	ref
Yes	642	211370	3.04	2.11 (1.90-2.35)***	1.21 (1.07-1.38)**
Hyperthyroidism					
No	1325	699624	1.89	ref	ref
Yes	31	11492	2.70	1.41 (0.99-2.02)	1.33 (0.92-1.92)
IHD					
No	987	610475	1.62	ref	ref
Yes	369	100642	3.67	2.25 (2.00-2.54)***	1.36 (1.19-1.56)***
Stroke					
No	1310	695656	1.88	ref	ref
Yes	46	15461	2.98	1.55 (1.15-2.07)**	0.85 (0.63-1.14)
CKD					
No	1204	662599	1.82	ref	ref
Yes	152	48517	3.13	1.71 (1.45-2.03)***	1.06 (0.89-1.26)
Hypothyroidism					
No	1343	706448	1.90	ref	ref

Yes	13	4668	2.78	1.46 (0.85-2.52)	1.15 (0.65-2.01)
Autoimmune diseases [†]					
No	1334	704142	1.89	ref	ref
Yes	22	6975	3.15	1.65 (1.08-2.51)*	1.34 (0.88-2.05)

Abbreviation: HR, hazard ratio; CI, confidence interval; RA, rheumatoid arthritis; DM, diabetes mellitus; IHD, ischemic heart disease; CKD, chronic kidney disease.

[†]Autoimmune diseases including psoriasis, SLE, systemic sclerosis, Sjogren syndrome, dermatomyositis, polymyositis, and vasculitis.

per 1000 person-years

[‡]Multivariate Cox proportional hazards regression model, including RA, sex, age (categorical), DM, hyperlipidemia, hypertension, hyperthyroidism, IHD, stroke, CKD, hypothyroidism, and autoimmune diseases.

* p<0.05, ** p<0.01, *** p<0.001

Table 3. Incidence density and RA cohort to non-RA cohort hazard ratios of hearing loss by sex, age, and comorbidity in the two cohorts

Variables	Non-RA cohort			RA cohort			RA cohort to non-RA cohort	
	Event no.	Person-years	Incidence density [#]	Event no.	Person-years	Incidence density [#]	HR (95% CI)	
							Crude	Adjusted [‡]
Sex								
Women	663	454249	1.46	314	110956	2.83	1.94 (1.69-2.22)***	1.95 (1.70-2.23)***
Men	264	117782	2.24	115	28130	4.09	1.82 (1.46-2.27)***	1.85 (1.48-2.30)***
Age, years								
20-39	40	98817	0.40	19	25020	0.76	1.89 (1.09-3.26)*	1.80 (1.02-3.16)*
40-59	355	295193	1.20	208	72982	2.85	2.37 (2.00-2.81)***	2.32 (1.95-2.76)***
≥ 60	532	178021	2.99	202	41084	4.92	1.63 (1.39-1.92)***	1.62 (1.37-1.90)***
Comorbidity								
DM								
No	765	514262	1.49	362	124722	2.90	1.95 (1.72-2.21)***	1.94 (1.71-2.20)***
Yes	162	57770	2.80	67	14363	4.66	1.66 (1.25-2.21)***	1.74 (1.30-2.32)***
Hyperlipidemia								
No	654	464753	1.41	320	113890	2.81	2.00 (1.75-2.28)***	1.96 (1.72-2.25)***
Yes	273	107279	2.54	109	25195	4.33	1.69 (1.36-2.11)***	1.74 (1.39-2.18)***
Hypertension								
No	481	402716	1.19	233	97031	2.40	2.01 (1.72-2.35)***	1.94 (1.66-2.28)***
Yes	446	169316	2.63	196	42054	4.66	1.76 (1.49-2.08)***	1.82 (1.54-2.16)***

Hyperthyroidism

No	909	563891	1.61	416	135733	3.06	1.90 (1.69-2.13)***	1.92 (1.71-2.16)***
Yes	18	8140	2.21	13	3352	3.88	1.76 (0.86-3.58)	1.72 (0.84-3.55)

IHD

No	671	491566	1.37	316	118909	2.66	1.95 (1.70-2.23)***	1.96 (1.71-2.24)***
Yes	256	80466	3.18	113	20176	5.60	1.75 (1.40-2.18)***	1.75 (1.40-2.19)***

Stroke

No	896	559458	1.60	414	136197	3.04	1.90 (1.69-2.13)***	1.90 (1.69-2.14)***
Yes	31	12573	2.47	15	2888	5.19	2.10 (1.13-3.89)*	2.18 (1.16-4.12)*

CKD

No	835	538065	1.55	369	124534	2.96	1.91 (1.69-2.16)***	1.94 (1.71-2.19)***
Yes	92	33967	2.71	60	14551	4.12	1.53 (1.11-2.12)*	1.73 (1.25-2.42)**

Hypothyroidism

No	917	569055	1.61	426	137393	3.10	1.92 (1.71-2.16)***	1.94 (1.73-2.18)***
Yes	10	2977	3.36	3	1692	1.77	0.53 (0.15-1.93)	0.69 (0.19-2.57)

Autoimmune diseases[†]

No	916	568956	1.61	418	135186	3.09	1.92 (1.71-2.15)***	1.94 (1.73-2.18)***
Yes	11	3076	3.58	11	3899	2.82	0.79 (0.34-1.82)	0.89 (0.38-2.07)

Abbreviation: RA, rheumatoid arthritis; HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; IHD, ischemic heart disease; CKD, chronic kidney disease.

[†]Autoimmune diseases including psoriasis, SLE, systemic sclerosis, Sjogren syndrome, dermatomyositis, polymyositis, and vasculitis.

[#] per 1000 person-years.

[‡] Model mutually adjusted for sex, age (continuous), DM, hyperlipidemia, hypertension, hyperthyroidism, IHD, stroke, CKD, hypothyroidism, and

1
2
3
4
5
6
7 autoimmune diseases.

8 * p<0.05, ** p<0.01, *** p<0.001
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table 4. Incidence density and hazard ratios of hearing loss associated with medication in patients with rheumatoid arthritis

Medicine use	N	Event no.	Person-years	Incidence density [#]	HR (95% CI)	
					Crude	Adjusted [†]
NSAIDs						
No	169	16	532	30.1	ref	ref
Yes	18098	413	138553	2.98	0.11 (0.07-0.18)***	0.12 (0.07-0.20)***
Prednisolone						
No	1673	60	11529	5.20	ref	ref
Yes	16594	369	127556	2.89	0.56 (0.43-0.74)***	0.53 (0.40-0.70)***
DMARDs						
Hydroxychloroquine						
No	12200	309	91284	3.39	ref	ref
Yes	6067	120	47801	2.51	0.75 (0.60-0.92)**	0.77 (0.62-0.95)*
Sulfasalazine						
No	5141	148	36176	4.09	ref	ref
Yes	13126	281	102909	2.73	0.68 (0.56-0.83)***	0.74 (0.61-0.91)**
Methotrexate						
No	9261	268	67188	3.99	ref	ref
Yes	9006	161	71897	2.24	0.57 (0.47-0.69)***	0.65 (0.53-0.79)***
Leflunomide						
No	15393	405	116118	3.49	ref	ref
Yes	2874	24	22967	1.04	0.30 (0.20-0.45)***	0.33 (0.22-0.50)***
TNF						
Etanercept						
No	16259	408	122506	3.33	ref	ref
Yes	2008	21	16579	1.27	0.39 (0.25-0.60)***	0.44 (0.28-0.68)***
Adalimumab						
No	17317	424	131303	3.23	ref	ref
Yes	950	5	7783	0.64	0.20 (0.08-0.48)***	0.23 (0.10-0.55)**

Abbreviation: HR, hazard ratio; CI, confidence interval RA, rheumatoid arthritis; NSAID, non-steroidal anti-inflammatory drug; DMARDs, disease-modifying antirheumatic drugs; TNF, tumor necrosis factor.

[#] per 1000 person-years.

[†] Model adjusted for sex, age, DM, hyperlipidemia, hypertension, hyperthyroidism, IHD, stroke, CKD, hypothyroidism, and autoimmune diseases.

* p<0.05, ** p<0.01, *** p<0.001

Table 5. Incidence density and hazard ratios for subtypes of hearing loss according to rheumatoid arthritis status

Types of hearing loss	Rheumatoid arthritis				Compared to non-TTH group	
	No		Yes		HR (95% CI)	
	Event no.	Incidence density [#]	Event no.	Incidence density [#]	Crude	Adjusted [†]
Sensorineural	249	0.44	144	1.04	2.38 (1.94-2.92)***	2.35 (1.91-2.89)***
Conductive	10	0.02	1	0.01	0.41 (0.05-3.21)	0.41 (0.05-3.23)
Mixed	668	1.17	284	2.04	1.75 (1.52-2.01)***	1.77 (1.54-2.03)***

ICD-9-CM: sensorineural, 389.10 and 389.12; conductive, 389.00; mixed, 388.2, 388.4, 389.2, and 389.9.

Abbreviation: HR, hazard ratio; CI, confidence interval; TTH,.

[#] per 1000 person-years.

[†] Model adjusted for sex, age (continuous), DM, hyperlipidemia, hypertension, hyperthyroidism, IHD, stroke, CKD, hypothyroidism, and autoimmune diseases.

*** p<0.001.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Fig 1. Flowchart showing selection of study cohorts


LHID, Longitudinal Health Insurance Database; RA, rheumatoid arthritis

For peer review only

1
2
3
4
5
6
7 Fig 2. Kaplan-Meier method estimated Cumulative incidence curves of hearing loss in
8 the two cohorts
9 RA, rheumatoid arthritis
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



190x107mm (300 x 300 DPI)



No. at risk

Non-RA cohort	73068	70979	68952	56187	35795	16093
RA cohort	18267	17445	16643	13564	8541	3836

199x209mm (300 x 300 DPI)

STROBE Statement

Checklist of items that should be included in reports of observational studies

Section/Topic	Item No	Recommendation	Reported on Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6,7
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7,8
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
Variables	7	(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	7,8
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Data sources/measurement	8*	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Bias	9	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8
Study size	10	Describe any efforts to address potential sources of bias	8
Quantitative variables	11	Explain how the study size was arrived at	7,8
Statistical methods	12	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7,8
		(a) Describe all statistical methods, including those used to control for confounding	8,9
		(b) Describe any methods used to examine subgroups and interactions	8,9
		(c) Explain how missing data were addressed	26
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	26
<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed			
		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	9
		(e) Describe any sensitivity analyses	9

Section/Topic	Item No	Recommendation	Reported on Page No
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10
		(b) Give reasons for non-participation at each stage	26
		(c) Consider use of a flow diagram	26
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10,22
		(b) Indicate number of participants with missing data for each variable of interest	26
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	10,27
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	10,27
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	10,23
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10,11,24
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	13,14
Other Information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.